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Abstract 
Molecular imaging is making possible the understanding of intricate biological processes in 
real-time in both healthy and diseased tissues. The ability to non-invasively locate biomarkers 
of disease with good sensitivity and specificity affords the ability to provide accurate and early 
diagnoses, and patient stratification for therapy. The chemokine receptor CXCR4 is one 
biomarker of interest, as it is overexpressed in many cancers, yet has low expression elsewhere 
in normal physiology. This thesis will document a method of combinatorial chemistry to 
construct libraries of new potential peptide-based imaging agents for positron emission 
tomography (PET) imaging. It will also incorporate the study of strain-promoted alkyne-azide 
cycloaddition (SPAAC) as a type of copper-free click chemistry used as a method for 
radiofluorination of biological structures.  
Chapter 2 discusses the synthesis of a library of N-terminal modified peptides created using a 
one-bead one-compound (OBOC) approach. Each peptide in the library contains a single 
fluorine atom incorporated through established SPAAC chemistry. The library of complete 
imaging agents was put through multiple stages of screening against CXCR4, resulting in the 
discovery of a peptide-based imaging agent with an IC50 of 138 µM.   
Chapter 3 discusses the development of a new 18F-labelled cyclooctyne-based prosthetic group 
for incorporation into azide-functionalized biological structures. This 18F-
azadibenzocyclooctyne (ADIBO-F) was radiolabelled from its toluenesulfonate precursor in 
21–35 % radiochemical yields, and subsequently incorporated into two cancer-targeting 
peptides through SPAAC chemistry. The result is two novel peptide‐based PET imaging agents 
that possess high affinities for their targets, the growth hormone secretagogue receptor 1a 
(GHSR‐1a) and gastrin‐releasing peptide receptor (GRPR), with IC50 values of 9.7 and 0.50 
nM, respectively. 
Chapter 4 discusses the synthesis of an OBOC library with an imaging moiety integrated 
within the peptide structures. A two-pool OBOC strategy was developed to distribute the 
fluorine-containing amino acid throughout the peptide sequence during library synthesis. The 
ADIBO-F prosthetic group from Chapter 2 was employed for simple translation of peptide 
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hits into their radiofluorinated counterparts. An on-bead two-colour screen was performed in 
one step and resulted in the discovery of three CXCR4-specific peptide-based imaging agents 
with micromolar affinities of 28, 86 and 109 µM.  
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Chapter 1  
1 Introduction 
1.1 Molecular Imaging 
Molecular imaging is a technique that combines molecular biology with non-invasive 
medical imaging and can be used to visualize and diagnose a large range of biological 
events and pathologies. It is routinely employed in the clinic to give a real-time image of 
the presence of important biomarkers or cell processes which allows for early diagnoses 
and monitoring of disease progression or treatment efficacy. Preclinical development of 
targeted therapeutics and understanding of the role of biomarkers in disease states can also 
be guided via molecular imaging.1 Many modalities of molecular imaging, such as 
magnetic resonance imaging (MRI) or computed tomography (CT), can rely on inherent 
biological contrast to give images with good resolution and specificity. However, some 
modalities require the administration of an external agent to provide the information that 
is detectable by the instrument of choice. This is particularly important in positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) imaging, 
where the presence of a radioisotope in the form of a radiopharmaceutical is essential to 
the imaging process. Furthermore, the specificity of molecular imaging agents can be 
improved by incorporating a targeting portion in addition to the imaging component. 
Targeted agents are often designed to bind to cell surface receptors or to be incorporated 
into enzymatic processes in the cell (Figure 1.1). The targeting moiety is most often a small 
molecule, a peptide, or an antibody, depending on the necessary pharmacokinetics and 
distribution for the intended imaging modality. 
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Figure 1.1 Design of a targeted molecular imaging agent. 
1.2 PET and Fluorine-18 
PET imaging is used for diagnostic imaging applications including oncology and 
neurology. It is a vital imaging technique as it offers a limitless depth of penetration, has 
high sensitivity, and gives a 3D image wherein the amount of radioactivity can be 
quantified using standard uptake values.  
As stated, PET imaging requires the presence of a radioactive atom to provide signal.  PET 
affords us with excellent sensitivity as an imaging modality, as only a small dose of the 
radiopharmaceutical is required to give a detectable signal (10-11 -10-12 M). Specifically, 
PET imaging requires a radionuclide that emits a positron; nuclei that are commonly used 
for PET imaging include 11C, 13N, 15O, 18F, 64Cu, and 68Ga because they decay by positron 
emission, also known as β+ decay. All of these radionuclides contain an excess of protons 
and decay by converting the extra proton into a neutron (p, n), releasing a positron and a 
neutrino. The positron then travels some short distance until it undergoes electron 
annihilation and creates two 511 keV gamma-ray photons that are released 180° apart from 
one another. PET cameras are set up so that the detectors are ringed around the subject in 
order to capture incidences of photons 180° apart. Lines of coincidence are recorded and a 
three-dimensional tomographic image with quantitative information can be constructed 
based on annihilation locations of coincident photon events.  
As previously discussed, there are multiple options of radioisotopes for PET, however 
fluorine-18 has chemical and physical characteristics that make it a preferred radioisotope 
for PET imaging. Fluorine-18 is routinely produced in a cyclotron by bombarding 18O-
enriched water with high-energy protons, making it comparatively easily accessible and 
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inexpensive to produce. Compared to other organic radioisotopes, 18F has a longer half-life 
of 109.8 minutes, which is generally sufficient to provide time for synthesis, delivery, and 
imaging without significant decay. Fluorine-18 also decays almost entirely by β+ decay 
(97%), making it an ideal isotope for PET imaging because the high quantity of annihilation 
events allows for high molar activities. Beyond the physical properties of fluorine-18, there 
are chemical properties that are considered beneficial over metallic radioisotopes that 
require chelation systems for incorporation into biomolecules. Fluorine is relatively small; 
this makes it a superior option in applications with small molecules in order to reduce steric 
bulk. Moreover, fluorine is most often introduced into molecules in the form of a stable 
carbon-fluorine bond which makes it more stable in vivo leading to low potential of 
radioactive accumulation in off-target tissues. An important consideration is the rapidity of 
incorporating the fluoride so that radiolabelling is facile and time-considerate. The 
synthetic conditions required to directly fluorinate targeting entities with [18F]fluoride are 
often too harsh for biomolecule-based targeting moieties. A few notable exceptions include 
non-canonical 18F-labelling strategies involving isotope exchange reactions from fluorine-
19 precursors, and aluminum fluoride constructs, which can all be achieved under mild 
conditions.87-89 Another common route is to incorporate 18F through a small molecule 
prosthetic group which is radiolabelled first and then attached to the biomolecule through 
milder reaction conditions. The radiochemical reactions to attach the prosthetic group must 
be rapid and involve minimal or simple purification steps. These include nucleophilic 
substitution (SN2) reactions, Michael additions, or click chemistry.  Some common 
fluorine-18 prosthetic groups are shown in Figure 1.2.2 
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Figure 1.2 Representative examples of common 18F prosthetic groups for straightforward 
labelling of biomolecules. 
1.3 Click Chemistry 
Click chemistry is a recently explored family of reactions, where the reaction method is 
rapid, bioorthogonal, produces no or harmless by-products, and can be conducted in 
physiologically friendly reaction conditions (physiological pH, room temperature, aqueous 
solution). The classic click chemistry reaction first introduced by Sharpless is the copper-
catalyzed Huisgen cycloaddition of an alkyne and an azide to produce a 1,4-triazole.3 This 
reaction is extensively used in radiolabelling and imaging because of its fast reaction rates. 
Additionally, amino acids with an azido or alkyne side chain are often incorporated into 
peptides and antibodies for easy modification with complementarily functionalized 
imaging entities ‒ generally fluorescent dyes. However, the cytotoxicity of residual copper 
is a concern in bio-applications,4 leading to research into copper-free click chemistry.  
The most prominent developments for copper-free click chemistry include Bertozzi’s 
Staudinger ligation,5 strain-promoted alkyne-azide cycloaddition (SPAAC),6,7 and inverse 
electron demand Diels-Alder (iEDDA).8,9 All of these reactions are used mostly for 
biological applications with nuclear imaging being an especially important area of research 
because the mild reaction conditions are desirable for radiolabelling. Of these copper-free 
click techniques, we chose to invest in SPAAC chemistry, as the reaction rates favour 
radiolabelling strategies and the components could be easily modified to suit our needs.  
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1.4 Strain-Promoted Click Chemistry 
SPAAC enlists the help of a strained alkyne in order to lower activation energy 
requirements of the click reaction and increase the rate constant. The reaction typically 
takes place between a strained alkyne and an organic azide (Figure 1.3). The 160° angle 
introduced to the sp-hybridized carbons of the alkyne by constraining it into an eight-
membered ring induces sufficient polarization for it to react without a copper catalyst, 
unlike a terminal alkyne. Additionally, electron-withdrawing groups can be added to the 
cyclooctyne to further lower the energy of the LUMO (lowest unoccupied molecular 
orbital).10,11  
 
Figure 1.3 Mechanism of the strain-promoted alkyne-azide cycloaddition reaction. 
SPAAC has rate constants of around 0.076 M-1 s-1 (difluorinated cyclooctyne, DIFO)
11
 to 
0.96 M-1 s-1 (biarylazacycloooctyne, BARAC)12 for different cyclooctynes (Figure 1.4), 
generally measured with the standard of benzyl azide in CD3OD or CD3CN. These numbers 
average out to be lower compared to those of iEDDA and normal copper-catalyzed click 
reactions, but higher than those of the Staudinger ligation. Some cyclooctynes employed 
in SPAAC increase strain through a fused cyclopropyl ring at the base, such as in 
bicyclononyne (BCN).13 The highest rate constants come from further strained 
cyclooctynes, such as those with benzene fused to either side of the eight-membered ring. 
BARAC is one of these alkynes ‒ with the quickest rate constant reported to date of 0.96 
M-1 s-1.12 However this also comes with a loss of stability; rearrangement often occurs in 
these structures over time.14 Azadibenzocyclooctynes (ADIBO or DIBAC) have a less 
ideal rate constant of around 0.31 M-1 s-1 but comes with much better shelf and solution 
stability.15 Variations on the structure of ADIBO, in which more electron-withdrawing 
groups have been added, are also seen to improve rate constants.16 Unfortunately, these 
modifications introduce synthetic complexity, which limits their availability. An acid or 
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amine handle incorporated into the R group in ADIBO provides a mode of bioconjugation 
for peptides and other biologically relevant structures.  
 
Figure 1.4 Structures of common cyclooctynes used in SPAAC chemistry. 
An inherent fault in SPAAC reactions using ADIBO and most other cyclooctynes is that 
two regioisomers are produced that are difficult to separate (Figure 1.5). For 
radiochemistry applications, the lengthy separation especially becomes an issue with the 
need for short syntheses to prevent radioactive decay. Some cyclooctynes, like BCN, do 
not form regioisomers but can create equally undesirable diastereomers or enantiomers.13 
Some work has been done with various cyclooctynes in which bulky functional groups are 
selectively placed near one side of the alkyne in order to favour one regioisomeric product 
due to steric bulk limitations.17,18 Similarly, Gröst and Berg reported a cyclooctyne that 
offers a single product with no isomers, although its reaction kinetics are not particularly 
impressive.19  
 
Figure 1.5 Regioisomers produced by SPAAC of ADIBOs. 
Nonetheless, SPAAC employing ADIBO has seen use for radiolabelled and biological 
applications. In a few cases, 18F is integrated into a cyclooctyne structure over multiple 
steps to produce a 18F-cyclooctyne prosthetic group (Figure 1.6A), to which an azide-
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containing targeting entity is then clicked.20–24 More commonly, the 18F is incorporated 
into an azide functionalized small molecule (Figure 1.6B), followed by a click reaction 
with an ADIBO-functionalized biological entity.25,26 
 
Figure 1.6 A variety of 18F prosthetic groups used in SPAAC radiochemistry.27 
1.5 Peptides as Targeting Moieties 
Peptides are especially useful as targeting components of radiopharmaceutical imaging 
agents.28 Their size and connectivity give them relatively short biological half lives that 
match the radioactive half lives of isotopes used. Because they circulate and clear quickly, 
this results in lower background levels of signal in PET or SPECT imaging. In addition, 
peptides are often highly selective and specific for their target. Peptide ligands for targeting 
can be discovered through rational design, where the side chains of the peptide sequence 
can be chosen based on the desired interactions with the known microenvironment in a 
binding pocket of a biological target. For targets of high complexity or with an unknown 
microenvironment, combinatorial methods are also used to discover novel peptide 
sequences. Although peptides are not usually very stable in biological conditions due to 
proteolysis, simple modifications to make the structures less like those of natural peptides 
are often employed, including amidation or acetylation of the C- and N-terminals, and 
incorporation of D-amino acids, unnatural amino acids or non-amino acid components. 
Many prosthetic groups are amenable to incorporation into peptides via coupling of free 
amines or carboxylic acids in the peptide structure.   
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Solid-phase peptide synthesis (SPPS) allows for straightforward synthesis and simple 
modifications of peptide structures. The approach uses an orthogonal protecting group 
strategy in order to couple amino acids one at a time onto a growing peptide chain built on 
resin from the C- to N- terminus. The fluorenylmethyloxycarbonyl protecting group 
(Fmoc) is base-labile and used to protect backbone amino groups on amino acids 
introduced. Various acid-labile protecting groups are used to protect side chain functional 
groups. Each amino acid is successively coupled to the amino-terminal of the growing 
peptide using a coupling reagent to form an active ester of the amino acid being introduced. 
Fmoc-removal using piperidine is then performed to generate a free amine for the next 
coupling step. Because the peptide is built on-resin, unused reagents and byproducts are 
washed away between steps. Final cleavage from the resin and side-chain protecting group 
removal can be afforded under acidic conditions (Figure 1.7). 
 
Figure 1.7 Scheme depicting the basic steps of Fmoc-based solid-phase peptide synthesis 
on an amine-functionalized resin. 
1.6 One-Bead One-Compound Libraries 
One-bead one-compound (OBOC) libraries and phage-display libraries are both 
combinatorial methods which allow the high-throughput screening of a diverse population 
of peptides against a target.29 These biologically active peptides can then later be 
conjugated to an imaging moiety to form a targeted imaging agent.30 OBOC libraries are a 
combinatorial method in which SPPS is used to produce a large number of chemically 
unique peptides each formed in multiple copies on a single resin bead. The process was 
developed by Kit Lam in 1991 as a method to rapidly chemically synthesize a large library 
of randomized peptides for screening for biological activity.31 Importantly, unlike many 
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other options to synthesize large libraries of peptides, such as phage display, OBOC can 
easily incorporate D-amino acids, unnatural amino acids, other small molecular weight 
components, and can overcome other limitations inherent of biological selection bias. 
Although OBOC libraries have been employed to discover new peptides that target cancer, 
among other diseases,29,32–39 there are relatively few reports of these peptides successfully 
modified into imaging agents.30,33,40–45 For direct identification of potential imaging agents, 
the integration of an imaging surrogate before screening for biological activity should be 
performed. This process would allow the imaging portion of the agent to be incorporated 
into the binding pocket of the target protein during solid-phase affinity studies. Peptide 
sequences where the imaging portion would prevent binding are excluded before further 
synthesis and complex binding assays. Conversely, peptides that bind better with the 
imaging portion present compared to the unmodified peptide would now be included in 
further studies. Whereas, when using the classic approach where the imaging moiety is 
added post-screening, these unmodified peptides may not have been included after the 
initial screen. To our knowledge, only three examples have been reported in the literature 
of such an approach, whereby the OBOC library consisted of imaging agents. In two cases, 
the design of such libraries was described: an N-terminally modified Re(CO)3 
organometallic peptide library was developed in our lab for the discovery of 99mTc SPECT 
imaging agents;46 and the synthesis of a peptoid DOTA-containing OBOC library for 
different metal chelates was described towards application for PET or MRI imaging.47 A 
recent publication describes the creation and on-bead screening of a focused OBOC peptide 
library containing the αvβ6‐targeting motif and a C-terminal 4-fluorobenzoyl group, which 
had some success in the discovery of lead peptides towards new 18F imaging agents.48 
An OBOC library is created by splitting the resin into n equal portions in n wells. To each 
well a different Fmoc-protected amino acid is added, along with the necessary coupling 
reagents. After coupling is achieved, the resin from all of the wells are combined, Fmoc-
deprotected, and split back into n wells. Subsequent coupling and deprotecting is 
performed and this process is repeated until the desired length of peptide is obtained 
(Figure 1.8). By splitting the resin in this way, the possibility for a bead to host a mixture 
of peptides is eliminated, and so each bead contains solely multiple copies of a single entity.   
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Figure 1.8 Two cycles of split-and-mix in forming an OBOC library using amino acids 
A, C, D, E, and F. 
This split-and-mix technique allows the diversity of the library to grow exponentially with 
each coupling step. For example, a library of octamers created from 17 different amino 
acids would result in a theoretical diversity of 178 ‒ around 7 billion possible unique peptide 
sequences. Since the amount of resin typically used is only 1 g (around 1.5 million 
TentaGel beads), less than 0.1% of possible peptides are expressed. This suggests that there 
is likely no redundancy in the library. Generally, some amino acids such as cysteine are 
excluded from those employed in the library so as to avoid complications such as cross-
linking. Likewise, methionine is also often not used because of its ability to easily become 
oxidized. Once the library has been synthesized, all remaining amino acid side-chain 
protecting groups are cleaved by an acidic solution, while the peptide stays attached to the 
resin through some linker. These linkers can be stable, or cleaved orthogonally through 
chemistries such as photolabile or disulfide linkers.49,50   
To screen the millions of peptides created from an OBOC library, the beads holding the 
peptides are combined with a biological entity of interest. A known target is not necessary, 
as often phenotypic screens are performed on cells. Specific targets can be used by either 
isolating a protein or by overexpressing the target in a cell line. The protein or cell line is 
generally fluorescently labelled in order to have the ability to detect the peptide beads that 
have binding interactions. Unbound cells or protein are washed away and beads are sorted 
based on affinity to the target. Alternatively, a protein linked to a magnetic bead could also 
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be used for screening and sorted from unbound library beads by a magnet in a “beads on a 
bead” approach.51,52 
Several approaches for sequence deconvolution of peptide hits exist, although it still 
remains the most laborious and challenging part of the OBOC screening process. Classical 
techniques included Edman degradation which is costly, time-consuming and is limited for 
peptides without N-terminal modifications or unnatural modifications in the peptide 
backbone. Matrix-assisted laser desorption/ionization (MALDI) tandem mass 
spectrometry (MS/MS) has emerged as a more rapid and cost-effective method to 
determine peptide sequences, and has no limits based on modifications, but has its own 
limitations based on fragmentation and ionization efficiency (Chapter 1.7). New 
technology has allowed for other emerging methods of deconvolution.  One-bead two-
compound (OBTC) bilayer approaches to chemically encoding beads involves parallel 
synthesis of small amounts of another molecule with the peptide53,54; these can even be 
oligonucleotides that can later be amplified by PCR and used to relate the DNA sequence 
to the corresponding amino acids used in the peptide construction.55  Ladder-synthesis 
approaches cap small amounts of peptide after each coupling, which leaves behind partial 
sequences that are more reliably observed in MS than peptide fragments via MS/MS.56,57  
Perhaps the most exciting recent advance in the field is the development of RFID-tagged 
chips that can be followed through each split-and-mix step for immediate and reliable 
identification of hit sequences, although this capability is still limited to smaller sized 
libraries.58  
1.7 Matrix-Assisted Laser Desorption/Ionization Mass 
Spectrometry 
MALDI is a frequently used tool for de novo sequencing of unknown peptides in either an 
on-bead process developed previously in our lab,50 or once the peptide has been 
photocleaved from the peptide into solution. This technique is often used over techniques 
like Edman degradation or OBTC because it is fast, cheap, and consistent. It also allows 
the recovery of small quantities of the peptide once completed. Cruikshank et al. reported 
the ability to sequence N-terminally modified Re-complexed peptides by MALDI MS/MS 
at single bead quantities of peptide.46  
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Tandem mass spectrometry is performed by selecting for the complete peptide at a 
determined parent ion m/z, fragmenting the peptide in the collision cell, and then collecting 
a complete mass spectrum of the fragments produced. In peptides, the location of the most 
common cleavage in low energy collisions is at the amide bonds between amino acids. 
Since almost each amino acid has a specific mass to charge ratio (m/z) for their residue, the 
mass difference between fragment peaks can be used to determine the amino acid sequence. 
Because this fragmentation produces both ionized fragments containing the N-terminus of 
the peptide or containing the C-terminus, it results in two series of peptide fragments 
detectable by MS/MS. The y ion series describes the result of amino acid loss from the N-
terminus. This means that all the fragments retain the original C-terminus of the peptide 
and the fragments have a charged N-terminus. Similarly, the b ion series reflects the result 
of amino acid cleavage from the C-terminus. All fragments in the b series retain the N-
terminus of the peptide and contain a charged C-terminus. An extension of the b series is 
also sometimes seen in lower incidence than b or y ions, wherein further fragmentation of 
the b series ions has occurred through the loss of a carbonyl; this is called the a ion series 
(Figure 1.9).59  
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Figure 1.9 A general hexamer peptide structure showing common fragmentation 
locations and examples of the fragments that are produced. 
Because this fragmentation occurs randomly within the peptide, some fragments may not 
appear in the MS/MS spectra with significant intensity. Because of this, sequencing by 
MALDI often has a low success rate. However, as long as there is sufficient overlap 
between the two series, full sequence deconvolution of the peptide is possible. 
Another difficulty encountered in sequencing by MS/MS lies in isobaric amino acids (those 
with similar masses such as leucine and isoleucine, or glutamine and lysine). Often, only 
one of the two matching amino acids are employed in the library. This unfortunately limits 
the structural diversity in peptides that could be generated in the library. Alternatively, 
peptides hits that include these mass residues can be resynthesized using either amino acid 
in the location of question and further screening can be performed with both options of 
which the sequences are now known.  
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1.8 G Protein-Coupled Receptors as Biological Targets 
G protein-coupled receptors (GPCRs) are a class of proteins with seven transmembrane 
domains. Because they are cell-surface receptors they are designed to detect extracellular 
molecules to start signal transductions within the cell, which makes them well-suited as 
biological targets for imaging agents. Their cell surface binding site allows for easy 
accessibility of the targeting entity which means imaging agents do not need to be cell 
permeable. Internalization through the receptor can occur, which often does lead to 
increased uptake of the tracer. Because GPCRs are such a large class of proteins, almost 
34% of FDA approved drugs target GPCRs, which means many are well-characterized and 
their roles in disease states have been explored.60 An important GPCR studied in cancer 
imaging is the gastrin-releasing peptide receptor (GRPR, also known as BB2) due to its 
high levels of overexpression in various cancers. The peptide bombesin has been found to 
bind to GRPR with high affinity and has been derivatized and used in multiple nuclear 
imaging applications.26,61–63  Our lab has also explored the growth hormone secretagogue 
receptor (GHSR-1a) as a target due to its differential expression in prostate cancer over 
benign prostate tissues.64 The endogenous ligand for GHSR-1a is the peptide ghrelin, and 
previous efforts in our lab have established ghrelin peptide analogues that can be modified 
with fluorescent dyes or radioligands for imaging.65–67  
1.9 C-X-C Chemokine Receptor 4 
The chemokine receptor CXCR4 is a GPCR that was first identified as a route of entry for 
HIV infection into CD4+ cells. Its natural ligand is CXCL12 (also known as SDF-1α), and 
together they are involved in various cellular pathways including chemotaxis, angiogenesis 
and proliferation.  Although this receptor has relatively low expression in normal tissues, 
it is expressed in over 23 types of cancers including breast and prostate cancer and 
melanomas.68 The expression of CXCR4 has been linked to metastatic forms of cancer due 
to its role in chemotactic pathways and homing to lymph nodes and bone marrow. It was 
determined in clinical prostate cancer biopsies that although the expression of CXCR4 is 
not significantly associated with Gleason score, frequency of CXCR4 expression is 35 
times higher in prostate cancer than non-malignant prostate tissue.69 Imaging of CXCR4 is 
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therefore an exciting target that could prove to be important for diagnoses and stratification 
of malignant and metastatic cancers.  
All forays into imaging CXCR4 have stemmed from research into anti-HIV-1 drugs. 
Antimicrobial self-defense peptide polyphemusin II was identified from the extracts of 
horseshoe crab (Tachypleus tridentatus) hemocytes.70 This peptide and its derivatives were 
found to be effective at inhibiting HIV-1 entry into cells via CXCR4.71 The peptide is 18 
amino acids in length, contains two disulfide bonds to form a beta-hairpin structure, and is 
amidated at the C-terminus. Initial structure-activity studies in order to improve potency 
and reduce cytotoxicity identified a peptide termed T22 (Tyr5,12, Lys7).72 Efforts to shorten 
the peptide and maintain potency eventually resulted in T140, a 14 amino acid peptide with 
a carboxylic acid C-terminus and a single disulfide bridge that retains high CXCR4 affinity 
(Figure 1.10a).73 FC131 is a cyclic pentapeptide which is the result of structure-activity 
studies to determine the main binding residues of T140; the N-terminal arginine, 
naphthylalanine, and tyrosine were found to be important for CXCR4 affinity (Figure 
1.10b).74 In addition, small molecule AMD3100 (Plerixafor) was also explored for its use 
as an HIV inhibitor as it is known to block the CXCR4 receptor but has since been used to 
treat cancer patients by mobilizing hematopoietic stem cells for transplantation (Figure 
1.10c).75,76  
 
Figure 1.10 CXCR4-targeting ligands with high affinities A) peptide T140 B) cyclic 
peptide FC131 C) AMD3100. 
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Of the PET imaging agents developed for CXCR4, T140 has been most often used as the 
scaffold of choice. In the first attempts to create a CXCR4 imaging agent, T140 was 
labelled on the N-terminus with various prosthetic groups. The use of [18F]4-fluorobenzoyl 
resulted in extremely high non-CXCR4 specific binding to red blood cells (RBCs) which 
proved not useful for imaging.77 Modifications of T140 with DOTA or NOTA for 68Ga, 
64Cu, and [18F]AlF incorporation lowered binding to RBCs but had significant liver and 
kidney uptake (up to 30% ID/g) and a decreased CXCR4 affinity.78–80 N-terminal 
acetylated T140 derivatives were also labelled on the Lys7 residue with [18F]2-
fluoropropionyl or [18F]4-fluorobenzoyl groups, showing lower blood retention, good 
CXCR4 affinity, but still high liver and kidney retention.81 Co-injection with excess cold 
tracer was shown to decrease liver uptake, which proves that the uptake is receptor-specific, 
but this strategy is not realistic for imaging purposes. FC131 has been modified to contain 
a DOTA chelator which was radiolabelled with 68Ga while retaining excellent CXCR4 
affinity.82 This radiopharmaceutical, called Pentixafor, is now being used in humans to  
image a variety of CXCR4-expressing cancers.83,84 A fluorine-18 labelled analogue 
utilizing [18F]AlF chemistry is being evaluated as an alternative.90 FC131 has also been 
labelled via a click reaction on a side chain with [18F]fluoroethylazide, which resulted in a 
poorer CXCR4 binder than FC131 on its own, and has not yet been explored for in vivo 
biodistribution or imaging.85 AMD3100 labelled with 64Cu has also shown promise as a 
PET imaging agent targeting CXCR4, but also has high liver uptake due to its positively 
charged nature, as well as issues with tumour to background ratios from plasma protein 
binding and potential transchelation of the metal.86  
Unfortunately, many of these peptide-based imaging agents, especially those employing 
fluorine-18, display poor pharmacokinetics and biodistribution in vivo which can likely be 
attributed to being based on the same peptide structure which carries through the 
physicochemical profile. New CXCR4-binding peptide-based imaging agents could be 
discovered through combinatorial methods and would likely result in a different 
pharmacokinetic profile.  
1.10  Summary 
The discovery of new peptide-based ligands for cancer targeting is important for the 
17 
 
development of the field of molecular imaging. OBOC libraries are often employed to 
discover such ligands. However, the addition of an imaging component to the peptide can 
often be detrimental to the binding affinity of the peptide sequence. To overcome this 
obstacle, we propose to integrate the imaging surrogate in the library prior to screening. 
We can discover new peptide-based imaging agents by screening a fluorine-containing 
OBOC library against a target of choice, wherein the imaging component of the molecule 
is essential to the binding affinity. Fluorine-18 radiochemistry is often performed through 
the use of click chemistry such that radiolabelling is fast, clean and simple. OBOC peptide 
libraries containing a clicked cyclooctatriazole moiety will be prepared so that a 18F-
labelled version would be easily prepared through SPAAC. The target of interest for this 
project is CXCR4, which has been implicated as a receptor highly expressed in various 
solid cancers. Although some CXCR4 imaging agents have been developed, they all stem 
from the same natural peptide structure which has resulted in a poor biodistribution profile 
common amongst all designs. An OBOC library of imaging agents could be used to screen 
for new CXCR4-targeting ligands. This will lead to the discovery of new fluorine-18 PET 
imaging probes for CXCR4-expressing cancers.   
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Chapter 2  
2 Incorporation of Fluorine into an OBOC Peptide Library 
by Copper-free Click Chemistry towards the Discovery 
of PET Imaging Agents 
2.1 Introduction 
New peptide-based imaging agents can be developed by rational design from known target-
specific peptides or through combinatorial methods. The synthesis of one-bead one-
compound (OBOC) libraries is a combinatorial method introduced by Lam et al. in 19911 
which involves split-and-mix synthesis to create millions of candidates from which 
peptide-receptor interactions can be discovered. Although the screening of classic OBOC 
libraries produces target-specific peptides,2–6 post-identification modification of these 
peptides to convert them into imaging agents often decreases binding affinity and creates 
the necessity for further modifications.7–11 However, few ventures have been made into 
making OBOC libraries of imaging agents.12–14   
Fluorine-18 is a preferred radioisotope for positron emission tomography (PET) imaging 
due to its half-life and availability; as such, incorporating a 19F-moiety into each entity of 
an OBOC library would create a library of complete imaging agents. This allows the 
imaging portion of the agent to be incorporated into the binding pocket of the target protein 
during affinity studies. Peptide sequences where the imaging portion would prevent 
binding would be excluded before further synthesis and complex binding assays. 
Conversely, peptides that bind better with the imaging portion present compared to the 
unmodified peptide are now included in further studies.  This enables high-throughput 
screening of millions of potential imaging agents. Tang et al. recently created a focused 
OBOC peptide library containing the αvβ6‐targeting motif and with a C-terminal 4-
fluorobenzoyl group and had some success in the discovery of lead peptides towards new 
18F imaging agents.14  
In this work, we aimed to develop an entirely randomized OBOC library containing an N-
terminal functionalized fluoride-containing moiety in hopes of producing imaging agents 
where the imaging portion is involved in receptor binding itself. Copper-free click 
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chemistry by strain-promoted alkyne-azide cycloaddition (SPAAC)15 is an increasingly 
popular technique for incorporating radioisotopes into biomolecular targeting agents due 
to its quick and mild reaction conditions.16–18 By using cyclooctyne-modified peptides and 
an azide-containing 19F-prosthetic group, this would allow for efficient and simple 
radiolabelling to produce the eventual 18F-imaging agent for PET imaging. 
The chemokine receptor CXCR4 has been implicated as a receptor of interest in a wide 
variety of cancers, especially in advanced and metastatic stages.19 Current peptide-based 
18F PET imaging agents that target CXCR4 have been based on the CXCR4-antagonist 
peptide T140, which was developed from the natural peptide polyphemusin II.20 
Unfortunately, many of these imaging agents display poor pharmacokinetics and 
biodistribution in vivo.21–24 New CXCR4-binding peptide-based imaging agents could be 
discovered through combinatorial methods.  
Our unique combinatorial library was screened on-resin against a U87 cell line that highly 
expresses CXCR4; beads that showed binding to the cells were isolated, and the sequences 
of the respective peptide portions were identified by MALDI tandem mass spectrometry 
(MS/MS). This demonstrates a methodology where novel fluorine-containing peptide-
based imaging agents can be discovered with straightforward translation into 18F PET 
imaging agents of CXCR4-expressing cancer. 
2.2 Results and Discussion 
2.2.1 Design and Synthesis 
The cyclooctyne moiety chosen for the construction of our library was 
azadibenzocyclooctyne-acid (ADIBO-COOH) 2.1 and was synthesized according to the 
methods of Chadwick et al.25  We chose to employ a PEG-based azide-containing 18F 
prosthetic group in order to offer some hydrophilicity to balance the large hydrophobic 
cyclooctyne. The fluorine-19 analogue 2.2 was synthesized and used in the construction of 
our library. An entirely randomized octamer OBOC library was synthesized on one gram 
of Tentagel S resin equipped with a photocleavable linker ((3‐amino‐3‐(2‐nitro-
phenyl)propionic acid) (ANP)). This allows protecting groups to be removed while the 
peptides stay attached to the resin beads; yet, the peptides can be later removed from resin 
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for sequencing. Seventeen natural amino acids (excluding cysteine, methionine, and 
isoleucine) were used in the split-and-mix process, after which the “clicked” portion 2.3 
was coupled onto the N-terminal of the combined library (Scheme 2.1). The result is a pool 
of about 1.5 million potential imaging agent candidates in which there is likely no 
redundancy of peptide sequences (less than 0.1% of potential diversity explored). 
 
Scheme 2.1 Synthesis of an octamer library on Tentagel resin using ADIBO-COOH 2.1 
and a PEG-based azide-containing fluoride 2.2.  X is any natural amino acid excluding 
cysteine, methionine, and isoleucine. 
2.2.2 Library Screening and Sorting 
The deprotected library beads were subjected to screening against U87.CD4.CXCR426 
cells that had been pre-incubated with a green Cell Tracker dye (ThermoFisher) to afford 
a way to visualize and sort the beads. In multiple wells the entire library was screened; 
approximately 500,000 cells were incubated with 20,000 beads in 3 mL of media per well 
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for one hour at 37 ⁰C. After incubation, some wells were visualized under fluorescence 
microscopy to confirm interactions between the cells and beads. Receptor-peptide 
interactions between the cells and beads were fixed with 4% paraformaldehyde, excess was 
quenched with 2 M glycine. Library beads were then recombined, media was decanted, 
and the beads were resuspended in PBS.  
Beads were sorted in aliquots using a Complex Object Parametric Analyzer and Sorter 
(COPAS, Union Biometrica)27 through two screening steps. Initially, all beads were 
collected that expressed any threshold of green fluorescence (dye λex/em = 492/517 nm) 
which resulted in narrowing the library hits to approximately 2,500 beads. This pool, 
however, can include false positive beads that exhibit autofluorescence of the Tentagel 
bead. These beads were then subjected to a second round of sorting by the COPAS with 
the green fluorescence threshold set to a higher limit (Figure 2.4). Hit beads during this 
step were sorted individually into 96 well plates and around 200 beads were collected. 
Visualization of the wells was performed under fluorescence microscopy to remove any 
remaining false positive results that were incorrectly identified as hits during the automated 
COPAS sort due to high levels of bead autofluorescence (Figure 2.5). Remaining beads 
were swollen in water and placed under a UV lamp for two hours in order to cleave peptides 
off the beads. The supernatant was then subjected to MALDI MS/MS for peptide sequence 
deconvolution (Figure 2.1). 
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2.2.3 MALDI MS/MS Deconvolution of Hit Peptide Sequences 
 
Figure 2.1 MALDI MS/MS deconvolution of a peptide hit from library screen; showing 
overlapping b and y series of fragments and demonstrating high fragmentation at b0. The 
isobaric amino acids lysine (K) and glutamine (Q) are both possibilities for mass 
fragments of ~ 128 Da. 
This step of the process proved challenging where some wells produced no observable MS 
product (possibly due to insolubility, incomplete cleavage from bead, etc.), or incomplete 
fragmentation in MS/MS leading to unsolvable sequences (a known issue in this 
deconvolution technique).28–30 In addition, the isobaric amino acids lysine and glutamine 
were both used in this library to promote diversity, but the corresponding residue mass was 
often observed in MS/MS spectra, which lead to multiple possible iterations of the hit from 
a single bead. An unexpected issue that arose was the high frequency of fragmentation 
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between the N-terminal amino acid and the imaging portion (at b0), causing less intense 
fragmentation patterns along the rest of the peptide backbone. 
2.2.4 Hit Peptide Synthesis and Validation of Target Specificity 
In the end, hit sequences that could be fully identified (Table 2.1) were resynthesized on 
Tentagel resin, including all possible combinations with Lys/Gln. Evaluation of each hit 
sequence using bulk beads allowed for a final determination of which peptide sequence 
iteration was legitimately a sequence that interacts with CXCR4. Peptides on resin were 
incubated with a single sequence in individual wells with either fluorescently-tagged 
U87.CXCR4.CD4 cells or U87.CD4 cells to serve as a control. Wells were imaged by 
fluorescent microscopy to re-confirm CXCR4 affinity and to select for peptides with 
CXCR4 selectivity. This step serves to remove any remaining false positives and to identify 
peptides that had off-target binding to the cells. Figure 2.2 displays an example where the 
four possible iterations of the ‘hit’ sequence shown in Figure 2.1 were synthesized 
separately on Tentagel resin. Of the combinations, only one (-YKFKRLWP-) shows good 
affinity to the CXCR4-expressing cells as well as strong selectivity for CXCR4 compared 
to the control cell line (cells in the top right image are in the background and not adherent 
to the beads). The other sequences show either low affinity, poor selectivity, or both. 
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Figure 2.2 On-bead screen of potential hits synthesized on Tentagel of the sequence      
F-PEG2-ADIBO-YXFXRLWP-NH2 where X = Q or K. This screen allows for 
confirmation of ‘hit’ sequence when isobaric amino acids are involved and also screens 
for selectivity to the target. 
2.2.5 Hit Peptide Synthesis and Validation of Target Affinity 
CXCR4-selective peptides were then resynthesized on Rink-amide resin and purified as 
the C-terminal amide. These peptides were subjected to a competitive binding assay using 
U87.CD4.CXCR4 cells and [125I]-SDF-1α as the radioligand. The lead compound from this 
target affinity assay was identified as F-PEG2-ADIBO-YKFKRLWP-NH2 and has an IC50 
of 138 µM. While other 18F peptide-based imaging agents for CXCR4 have higher 
affinities, they are primarily based on the same polyphemusin peptide sequence and often 
have comparable drawbacks when it comes to in vivo behaviour.21–24 This OBOC library 
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produced a new sequence that can serve as a starting point for further development towards 
novel CXCR4-targeted imaging agents. 
2.3 Conclusions 
Overall, we have developed an OBOC approach as a combinatorial method to produce a 
large-scale library of peptide imaging agent candidates. This can be useful for the screening 
against any target of interest for imaging purposes. Our library conveniently includes the 
chosen imaging moiety (fluorine-18, with fluorine-19 as a standard) through copper-free 
click chemistry in order to produce hits that can be easily translated into radiolabelled 
imaging agents. Although the discovery of imaging agents from this method still proves to 
be laborious and fraught with challenges, the screening steps directly produced a lead 
imaging agent with micromolar affinity Modifications based on this sequence could be 
explored to further improve the affinity for CXCR4. Exciting new advancements in 
technologies for tracking synthetic histories of solid-phase syntheses with DNA tags or 
RFID microtransponders are highly complementary to this sort of application.31,32 As 
Improvements upon some of the challenges encountered in this library development will 
be explored in future generations of OBOC imaging agent libraries. Focused library 
synthesis would aid in the throughput of sequence deconvolution when part of the sequence 
is known, as well as likely produce higher affinity hits.5,14 Other library conformations 
where the imaging moiety is dispersed through the peptide sequences could also be 
explored to promote discovery of imaging agents where the imaging moiety is integrated 
into the binding pocket.  
2.4 Experimental 
2.4.1 General Experimental 
All reactions were carried out under a nitrogen atmosphere using oven-dried glassware. 
Dichloromethane (DCM) was distilled over CaH2. Other reagents and solvents were used 
as received from Sigma-Aldrich, Alfa Aesar, or Fisher Scientific. Amino acids and resins 
were received from Peptides International or Chem. Impex.. Flash chromatography was 
performed on a Biotage Isolera Prime automated flash purification system. Biotage SNAP 
KP-Sil 10 g, 25 g, or 50 g cartridges (45-60 micron) were used with flow rates of 12, 25, 
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and 50 mL/min respectively for gradient solvent systems. Fractions were monitored and 
collected by UV absorbance using the internal UV detector set at 254 nm and 280 nm. 
NMR spectra were recorded on a either an Agilent Mercury VX 400 or a Bruker AvIII HD 
400 MHz Spectrometer. Chemical shifts are recorded in parts per million. EI and CI HRMS 
was measured on a Thermo Scientific DFS (Double Focusing Sector) mass spectrometer. 
Peptides were purified by preparative reverse-phase HPLC-MS and analytical reverse-
phase HPLC-MS was performed to assess purities. The system consists of a Waters 600 
controller, Waters Prep degasser, Waters Quattro micro Mass, and Waters Mass Lynx 
software. The UV absorbance was detected using a Waters 2998 Photodiode array detector. 
A preparative column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or 
analytical column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The 
solvent system runs gradients of 0.1 % trifluoroacetic acid (TFA) in ACN and 0.1 % TFA 
in water at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash. 
After purification, the collected fractions were frozen at -78 °C and lyophilized.  
2.4.2 Small Molecule Synthesis 
5-[11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl]-4-oxobutanoic Acid (ADIBO-
COOH) (2.1) 
ADIBO-COOH 2.1 was prepared as described by Chadwick et al.25 1H NMR (400 MHz, 
CDCl3): δ 7.67 (d, J = 7.5 Hz, 1H), 7.50 – 7.20 (m, 7H), 5.16 (d, J = 13.9 Hz, 1H), 3.70 (d, 
J = 13.9 Hz, 1H), 2.72 (ddd, J = 16.6, 8.9, 5.2 Hz, 1H), 2.60 (ddd, J = 17.0, 8.9, 5.2 Hz, 
1H), 2.36 (ddd, J = 16.8, 6.4, 5.1 Hz, 1H), 1.99 (ddd, J = 16.6, 6.6, 5.2 Hz, 1H).13C NMR 
(100 MHz, CDCl3): δ 176.1, 172.6, 151.2, 147.8, 132.4, 129.3, 128.7, 128.6, 128.5, 128.03, 
127.4, 125.7, 123.2, 122.8, 115.2, 107.6, 55.8, 29.7, 29.6. HRMS (EI): m/z calculated for 
C19H15NO3 : 305.1052; found: 305.1045. 
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Scheme 2.2 Scheme for synthesis of 2.2. 
2,2’-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (2.4) 
Tosyl chloride (7.61 g, 39.9 mmol) was slowly added to a solution of triethylene glycol 
(2.00 g, 13.3 mmol) in triethylamine (50 mL). The reaction mixture was stirred overnight 
at room temperature, and the solvent was removed by rotary evaporation. The product was 
washed with water and extracted into EtOAc. The combined organic layers were dried over 
MgSO4 and concentrated under reduced pressure. The product was isolated by automated 
Isolera flash column chromatography (SNAP KP-Sil cartridge, 12-100% EtOAc/hexanes) 
yielding the ditosyl 2.4 (2.77 g, 63%) as an orange solid. 1H NMR (400 MHz, CDCl3): δ 
7.77 (d, J = 8.0 Hz, 4 H), 7.33 (d, J = 8.0 Hz, 4 H), 4.12 (t, J = 4.8 Hz, 4 H), 3.63 (t, J = 
4.8 Hz, 4 H), 3.50 (s, 4 H), 2.42 (s, 6 H). 13C NMR (100 MHz, CDCl3): δ 145.0, 133.0, 
129.9, 128.0, 70.7, 69.3, 68.8, 21.7. HRMS (EI): m/z calculated for C20H26O8S2 : 458.1069; 
found: 458.1079. 
2-(2-(2-azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (2.5) 
A solution of ditosyl 2.4 (90.0 mg, 1.96 mmol) and sodium azide (113 mg, 1.72 mmol) in 
dry DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was 
quenched with water and extracted into DCM. The organic fractions were washed with 
water, brine, and dried over MgSO4. The combined organic layers were concentrated under 
reduced pressure and the product was isolated by automated Isolera flash column 
chromatography (SNAP KP-Sil cartridge, 17-100% EtOAc/hexanes), yielding the azide 
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2.5 (57.0 mg, 81%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.89 (d, J = 8 Hz, 2 H), 
7.34 (d, J = 8 Hz, 2 H), 4.16 (t, J = 5 Hz, 2 H), 3.70 (t, J = 5 Hz, 2 H), 3.64 (t, J = 5 Hz, 2 
H), 3.60 (s, 4 H), 3.36 (t, J = 5 Hz, 2 H), 2.44 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 
144.9, 133.1, 129.9, 128.1, 70.9, 70.7, 70.2, 69.4, 68.9, 50.8, 21.8. HRMS (CI): m/z 
calculated for C13H20N3O5S [M+H]
+ : 330.1118; found: 330.1123. 
1-azido-2-(2-(2-fluoroethoxy)ethoxy)ethane (2.2) 
A commercially available solution of 1.0 M TBAF in THF (6.94 mL, 6.94 mmol) was 
added to a solution of azide 2.5 (1.14 g, 3.47 mmol) in t-BuOH (30 mL). The reaction 
mixture was stirred at 100 °C overnight. The reaction mixture was quenched with water 
and extracted into DCM. The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure.  The product was purified by automated Isolera flash 
column chromatography (SNAP KP-Sil cartridge, 0-2% MeOH/DCM), yielding the 
product 2.2 (390 mg, 64%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3): δ 4.60 (t, J 
= 2.8 Hz, 1 H), 4.52 (t, J = 2.8 Hz, 1 H), 3.77 (t, J = 2.8 Hz, 1 H), 3.72 (t, J = 2.8 Hz, 1 H), 
3.70-3.66 (m, 6 H), 3.38 (t, J = 3.2 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 83.3 (d, 
1JCF 
= 169 Hz), 71.0, 70.9, 70.7 (d, 2JCF = 19.6 Hz), 70.3, 50.8. HRMS (CI): m/z calculated for 
C6H12FN3O2 [M+H]
+ : 178.0986; found: 178.0990. 
F-PEG2-ADIBO-COOH (2.3) 
ADIBO-COOH 2.1 (0.158 g, 0.52 mmol) and 2.2 (0.115 g, 0.65 mmol) were dissolved in 
5 mL of a 3:2 EtOH:H2O mixture. The solution was shaken for two hours, diluted with 
water, frozen, and lyophilized. The product was purified as a combination of its two 
inseparable regioisomers by automated Isolera flash column chromatography (SNAP KP-
Sil cartridge, 2-15% MeOH/DCM) to yield 2.3 as a yellow oily solid (0.200 g, 80%). 1H 
NMR (400 MHz, CDCl3) δ 7.91 – 7.07 (m, 8H), 6.12 (d, J = 16.7 Hz, 1H), 4.73-4.64 (m, 
1H), 4.60-4.51 (m, 2H), 4.50 – 4.43 (m, 1H), 4.43 (d, J = 16.6 Hz, 1H), 4.02-3.91 (m, 2H), 
3.79 – 3.69 (m, 2H), 3.69 – 3.55 (m, 4H) 2.58 – 2.26 (m, 2H), 2.0 (m, 1H), 1.99 – 1.62 (m, 
1H). HRMS (EI): m/z calculated for C25H27FN4O5 : 482.1965; found: 482.1972. 
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2.4.3 OBOC Library Synthesis 
The library was synthesized using standard Fmoc solid-phase peptide synthesis (SPPS) 
conditions on a Biotage SyroWave automated peptide synthesizer using a split-and-mix 
technique in the dark. Briefly, 1 g of Tentagel S-NH2 resin (90 µm, 0.29 meq/g) was 
swelled in DCM and manually coupled to Fmoc-ANP-OH linker (4 eq) using HCTU (4 
eq) and N-N-diisopropylethylamine (DIPEA) (8 eq) in DMF for two hours. The resin was 
split into seventeen vessels. Fmoc removal was achieved using 40% piperidine in 
dimethylformamide (DMF) over two steps (5 min and 15 min). Each well was coupled to 
a different Fmoc-amino acid (4 eq) using HCTU (4 eq) and DIPEA (8 eq) in DMF for one 
hour. After each Fmoc-deprotection/coupling cycle, the resin was recombined into one 
pool and then divided into seventeen vessels again. This was repeated eight times to 
achieve peptides eight amino acids in length. To the combined library, F-PEG2-ADIBO-
COOH 3 (1.6 eq) was coupled using HATU (1.6 eq) and DIPEA (3.2 eq) in DMF for 5 
hours. Full deprotection was achieved with 95% TFA, 2.5% triisopropylsilane (TIPS) and 
2.5% water for 5 hours. The library was rinsed thoroughly with DMF, DCM, MeOH, and 
stored in 70% EtOH/H2O.  
2.4.4 Hit Peptide Synthesis 
Peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave 
automated peptide synthesizer. Fmoc-protected Rink amide MBHA or Tentagel S- NH2 
resin was used as a solid support after swelling in DCM. Fmoc removal was achieved using 
40% piperidine in dimethylformamide (DMF) over two steps (30 sec and 12 min). Amino 
acids were coupled with the Fmoc-protected amino acid (4 eq), HCTU (4 eq) and DIPEA 
(8 eq) in DMF/N-methyl pyrrolidinone (NMP) over 1 hour. The acid 2.3 was manually 
coupled to the N-terminus using 1 equivalent of 2.3, 1 equivalent of HATU and 2 
equivalents of DIPEA in DMF.  
Tentagel peptides were deprotected using a solution of 95% TFA, 2.5% TIPS and 2.5% 
water for 4 hours. Beads were rinsed thoroughly with DMF, DCM, MeOH, H2O and stored 
in 70% EtOH/H2O.  
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Full cleavage of the Rink-amide peptides from resin along with removal of side chain 
protecting groups was achieved with a solution of 95% TFA, 2.5% TIPS and 2.5% water 
over 5 h. The cleaved peptides were precipitated in cold tert-butyl methyl ether (TBME) 
and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide dissolved 
in water, frozen at -78 °C and lyophilized. The peptides were then purified by preparative 
reverse-phase HPLC-MS over gradients of acetonitrile (0.1% TFA) in water (0.1% TFA).  
The peptides were isolated in >98% purity by analytical RP-HPLC. Peptides are a 
combination of the two inseparable regioisomers.  
Table 2.1 Sample list of select peptide sequences resynthesized for in vitro validation. 
All are coupled to 2.3 on the N-terminal and are amidated on the C-terminal. 
Amino Acid Sequence  [M+H]+  m/z theoretical  [M+H]+  m/z found 
-YKFKRLWP- 1600.86 1600.83  
-HLTKYWET- 1540.74 1540.55 
-HLTQYWET- 1540.70 1540.50 
-AKEDNFRN- 1456.68 1456.54 
-AQEDNFRN- 1456.64 1456.47 
-NDEDEEYA- 1447.54 1447.39 
-RLDSHDPK- 1430.70 1430.56 
-RLDSHDPQ- 1430.66 1430.51 
-NFKEFDHA- 1452.69 1452.53 
-NFQEFPHA- 1452.65 1452.45 
-FLFWGPAG- 1357.65 1357.52 
 
37 
 
 
Figure 2.3 Sample HPLC chromatogram (UV trace, 25-85% ACN/H2O with 0.1% TFA) 
of a purified peptide F-PEG2-ADIBO-YKFKRLWP-NH2. 
2.4.5 Cell Culture 
U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R. 
Littman. U87.CD4.CXCR4 cells were maintained in DMEM – high glucose (Sigma) 
containing 15% fetal bovine serum (FBS), 1 μg mL-1 puromycin, 300 μg mL−1 G418, and 
1× penicillin–streptomycin. U87.CD4 cells were maintained in DMEM – high glucose 
(Sigma) containing 10% FBS, 300 μg mL−1 G418, and 1× penicillin–streptomycin. All cell 
lines were cultured at 37 °C in humidified atmosphere with 5% CO2 and passaged 2 to 3 
times per week. 
2.4.6 Library Screening 
U87.CD4.CXCR4 cells at 80% confluency were incubated with 5 µM CellTracker™ Green 
CMFDA Dye (ThermoFisher) in serum-free DMEM media for 30 min at 37 °C. Dye was 
aspirated, and cells were lifted using an enzyme-free dissociation solution (Sigma). Cells 
were counted and resuspended in serum-free DMEM at 500,000 cells/mL. Library beads 
were suspended in phosphate-buffered saline (PBS) and dispersed in 6-well plates at 
~20,000 beads/well (entire library is ~1.5 million beads). Cells were added to each well (1 
Default file
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mL, 500,000 cells) and total volumes were brought up to 3 mL with DMEM. Plates were 
shaken at 550 rpm for 1 hour at 37 °C. To each well, 0.33 mL of 37% paraformaldehyde 
was added for a final concentration of 4%. Fixing was quenched by the addition of 2 M 
glycine to a final concentration of 20%. The entire library of beads was recombined and 
rinsed with PBS repeatedly then suspended in PBS. Aliquots of this solution were added 
to the sample cup of a COPAS instrument (Union Biometrica) and diluted into the 
appropriate sheath reagent. Beads were sorted at ~20 events/s and excited by a 488 nm 
lamp to select for beads (via length (TOF) and optical density (Ext)) as well as to sort for 
fluorescence (green λem = 510±23 nm) (Figure 2.4A-B & 2.5A-B). Beads were collected in 
bulk (~2500 events), rinsed, and then re-added to the sample cup and sorted with a higher 
set threshold of fluorescence for sorting (Figure 2.4C). In this sort, hit beads were deposited 
into individual wells of a 96 well plate (~200 events) (Figure 2.5C-D). Wells were imaged 
by confocal fluorescent microscopy to remove any remaining false positive beads (Figure 
2.5D). Confocal fluorescence microscopy was performed on a Nikon A1R Confocal Laser 
Microscope with a 488 nm laser for excitation and the emission range set to 500-550 nm. 
 
Figure 2.4 Screenshots of COPAS software showing A) gating selection for bead-sized 
objects based on size (TOF) and optical density (Ext); B) sorting selection for initial 
screen based on bead size and above-average green fluorescence (λem = 510±23 nm); C) 
sorting selection for second round with higher threshold of green fluorescence. 
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Figure 2.5 Confocal fluorescence images of A) library pool after incubation with 
U87.CD4.CXCR4 cells tagged with CellTracker Green CMFDA; B) library beads after 
initial screen showing some hit beads with various degrees of cell coverage; C) isolated 
hit library bead in a well of a 96 well plate after second sorting round; D) isolated false 
positive bead displaying high autofluorescence. 
2.4.7 MALDI MS/MS 
Hit beads from the library screen were suspended in 50 µL of water in individual wells of 
96-well plates and placed under UV light (365 nm) for 2 hours to achieve cleavage from 
the bead due to the ANP linker. The aqueous solution was mixed with matrix α-cyano-4-
hydroxycinnamic acid (CHCA) in acetonitrile and placed onto the MALDI target. MALDI 
TOF/TOF was performed on an AB Sciex TOF/TOF 5800 by the facility manager of the 
MALDI Mass Spectrometry Facility at the London Regional Proteomics Centre.  
2.4.8 Selectivity Analysis Assay 
U87.CD4.CXCR4 or U87.CD4 cells at 80% confluency were incubated with 5 µM 
CellTracker™ Green CMFDA Dye (ThermoFisher) in serum-free DMEM media for 30 
min at 37 °C. Dye was aspirated, and cells were lifted using an enzyme-free dissociation 
solution (Sigma). Cells were counted and resuspended in serum-free DMEM at 150,000 
cells/mL. Tentagel beads expressing re-synthesized potential hit sequences were suspended 
in phosphate-buffered saline (PBS) and dispersed in 12-well plates at ~10,000 beads/well. 
Cells were added to each well (1 mL, 150,000 cells) and total volumes were brought up to 
2 mL with DMEM. Plates were shaken at 550 rpm for 1 hour at 37 °C. Wells were directly 
imaged using confocal fluorescent microscopy (Nikon). 
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Figure 2.6 Uncropped Images of Figure 2.2 to further display selectivity. 
2.4.9 Competitive Binding Assays 
In vitro CXCR4 affinity of final hit peptides were determined through competitive binding 
assays using U87.CD4.CXCR4 cells with [125I]-SDF-1α as the radioligand (Perkin Elmer). 
The compound of interest (30 µL, at concentrations ranging from 10−6 to 10−2 M) and 
20,000 cpm of [125I]-SDF-1α (20 pM) were mixed with the binding buffer (20 mM HEPES, 
0.5% BSA in PBS, pH 7) in 1.5 mL Eppendorf Protein LoBind vials. A suspension of 
U87.CD4.CXCR4 cells (50,000 cells in 50 µL) was added to each vial to give a final 
volume of 300 μL. The vials were shaken at 550 rpm for 20 minutes at 37 °C. Immediately 
after the incubation, the vials were centrifuged at 13,000 rpm for 5 minutes and the 
supernatant removed. The cell pellet was washed with 500 μL of 50 mM Tris buffer (pH 
7) and centrifuged again. The amount of [125I]-SDF-1α bound to the cells was measured 
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using a gamma counter (PerkinElmer). IC50 values were determined by non-linear 
regression analysis to fit a 4-parameter dose response curve using GraphPad Prism 
(Version 6.0c). All data points were obtained in triplicate.  
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Chapter 3  
3 A Compact and Synthetically Accessible Fluorine-18 
Labelled Cyclooctyne Prosthetic Group for Labelling of 
Biomolecules by Copper-free Click Chemistry 
3.1 Introduction 
Positron emission tomography (PET) is an important molecular imaging technique used to 
non-invasively visualize and diagnose many different biological events and pathologies.1 
The use of fluorine-18 as a PET radionuclide is popular due to its relatively long half life 
(~110 minutes) among non-metallic isotopes, allowing ample time for radiosynthesis as 
well as other favourable nuclear and chemical properties.2 Due to its small size, fluorine-
18 has been incorporated into imaging agents of various complexities from small molecules 
to larger biomolecules.3-5 However, an important consideration is the method of 
incorporating the fluoride such that rapid and facile radiolabelling is achieved. Direct 
labelling of a molecule with fluoride-18 can require harsh nucleophilic conditions, which 
the biologic “targeting” portion of an agent may not withstand. Instead, small-molecule 
fluorine-18 prosthetic groups are labelled first and used to introduce the radionuclide to a 
biomolecule under milder conditions. Careful selection of these prosthetic groups is 
necessary to ensure that the addition does not elicit a change in biological function.  
The copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition  (CuAAC) reaction as a form 
of “click chemistry” was first introduced by Sharpless in 2001.6 This concept has since 
been widely explored in applications to label biomolecules with various imaging 
components under bioorthogonal conditions. The click reaction satisfies the requirement 
of milder reaction conditions for appending a prosthetic group to a biomolecule; it also 
boasts the benefits of fast reaction kinetics and lack of by-products. Because of these 
properties, this reaction lends itself particularly well to synthetic radiolabelling strategies 
for the production of nuclear imaging agents.7 This is especially true for shorter-lived PET 
isotopes such as fluorine-18.  For the use of CuAAC in in vivo applications, the complete 
removal of copper reagents remaining after reactions is necessary in order to avoid 
cytotoxicity issues. These extra purification steps unfortunately hinder the efficiency of the 
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radiosynthesis. The strain-promoted alkyne-azide cycloaddition (SPAAC) reaction is a 
convenient copper-free alternative to click chemistry reactions which avoids cytotoxic 
copper reagents.8  
Both CuAAC and SPAAC have been extensively used to label biomolecules such as 
proteins, oligonucleotides, peptides and other targeting entities with fluorine-18.9-13  In 
SPAAC examples, the most commonly used cyclooctynes are azadibenzocyclooctynes 
(ADIBOs), due to their relatively fast reaction kinetics (0.4-0.9 M-1s-1 depending on 
modifications) and long-term stability compared to other reported cyclooctynes.14-15 
ADIBO is commonly synthesized with an acid or amine handle, which allows for 
conjugation to biomolecules through standard coupling techniques (Figure 3.1A). 
Fortunately, there have been a wide variety of fluorine-18 azide-containing prosthetic 
groups developed for copper-catalyzed click reactions which are also employable with 
cyclooctyne-modified biomolecules, allowing for quick transition into PET imaging 
agents.16 
 
Figure 3.1 Structures of A) non-labelled ADIBOs where R contains an acid or amine for 
conjugation to a biomolecule, B) ADIBOs that have been indirectly labelled with 
fluorine-18 and C) ADIBOs that have been further derivatized into fluorine-18 prosthetic 
groups. 
To approach radiolabelling via the SPAAC reaction from the opposite direction, easily-
accessed azide-containing biomolecules and targeting moieties can be employed. The 
complementary piece to this azido-derivatized biomolecule necessitates an 18F-labelled 
cyclooctyne. 
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Indirect labelling of ADIBOs was first shown by using the prosthetic group 4-
succinimidyl-[18F]fluorobenzoate to incorporate fluorine-18 into an amine-functionalized 
ADIBO (Figure 3.1B).17-18 ADIBOs have also been shown to be sufficiently stable for 
direct fluorine-18 labelling conditions. Previous approaches in the literature make use of 
ADIBO-NH2 by coupling a carboxylic acid-functionalized linker to the amine tail. This 
alkyl or PEG linker connects the ADIBO to a suitable leaving group for 18F-labelling of 
the resulting molecule (Figure 3.1C).19-20 Recently, an oxodibenzocyclooctyne was 
labelled with fluorine-18 showing reactivity with micromolar concentrations of azide-
modified bioconjugates.21  While these are exciting and useful developments for the 
utilization of copper-free click techniques in fluorine-18 radiolabelling of peptides, these 
constructs can be fairly large and high in molecular-weight for a prosthetic group. Because 
the copper-free click reaction is not regioselective, this long tail also results in significantly 
different 1,4 and 1,5 regioisomers, which could affect receptor binding or pharmacokinetic 
properties of the imaging agent. Furthermore, the expense of ADIBO-NH2 and ADIBO-
COOH can be prohibitive when investigating the discovery of new imaging agents. We 
propose a new fluorine-containing ADIBO that seeks to: 1. simplify synthesis from 
inexpensive, readily-available starting materials; 2. minimize structural difference in 
regioisomers produced by the SPAAC reaction; 3. reduce the size and molecular weight of 
the prosthetic group in comparison to those previously reported.  
3.2 Results and Discussion 
3.2.1 Synthesis of ADIBO-F 
We report a new fluorine-containing ADIBO that is synthetically accessible in nine linear 
steps via modifications to the Popik synthesis.22-23 In brief, the inexpensive starting 
material dibenzosuberenone 3.1 was converted to oxime 3.2. A subsequent Beckmann 
rearrangement produces lactam 3.3, which is then reduced by lithium aluminum hydride to 
its secondary amine 3.4. The amine is acylated with bromoacetyl bromide to produce 3.5 
with a handle for functionalization from the azadibenzocyclooctene core. Compound 3.5 
is subsequently transformed into the alcohol 3.6, which is stable to the reaction conditions 
used for the formation of the cyclooctyne. Bromination across the cyclooctene and 
subsequent elimination with potassium tert-butoxide produces the cyclooctyne 3.7. 
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Tosylation of the alcohol to produce a suitable leaving group results in the precursor of the 
prosthetic group 3.8. Conversely, the fluorine-19 standard of the prosthetic group can be 
formed by halide exchange of the bromide 3.5 to fluoride using tetrabutylammonium 
fluoride to produce 3.9. This can be followed by a similar bromination/elimination of the 
cyclooctene to form the cyclooctyne 3.10 (Scheme 3.1).  
 
Scheme 3.1 Branching synthesis of both ADIBO-OTs 3.8 and [19F]ADIBO-F 3.10 
standard via modifications to the Popik synthesis22-23 of ADIBOs. 
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3.2.2 Radiolabelling of a [18F]ADIBO-F Prosthetic Group 
The tosylate precursor 3.8 of this novel ADIBO has been labelled with dry [18F]fluoride 
under basic conditions in the presence of Kryptofix 222. The prosthetic group [18F]3.10 
was purified by semi-preparative HPLC and isolated in greater than 98% radiochemical 
purity to give 21-35% decay-corrected radiochemical yields in under 30 minutes of total 
reaction and purification time (Scheme 3.2).  
 
Scheme 3.2 Radiosynthesis of [18F]ADIBO-F [18F]3.10. 
3.2.3 Copper-Free Click Radiolabelling of Model Peptides using 
[18F]ADIBO-F 
The potential for [18F]ADIBO-F [18F]3.10 to be employed as a prosthetic group has been 
tested with two peptides that are known to be effective for targeting G protein-coupled 
receptors (GPCRs) overexpressed in a variety of cancers. The first example of using our 
novel prosthetic group for radiolabelling is demonstrated by incorporating it into [Dpr-
3(octanoyl),Lys19]ghrelin(1-19). It has been shown that peptides with various imaging 
moieties connected at the Lys19 of this peptide sequence target the GHSR-1a receptor with 
nanomolar affinities.24-26 By modifying Lys19 to a lysine-azide (3.11), imaging moieties can 
be linked to the peptide by click reactions resulting in candidate imaging agents. Through 
triazole formation at the azide, our new cyclooctyne prosthetic group was linked to this 
peptide in 15 minutes at 70 °C, which is milder than typical nucleophilic fluoride addition 
conditions. The SPAAC reaction allows this labelling to proceed in neutral conditions in 
absence of any other reagents, and at a temperature that allows for increased reaction 
kinetics while ensuring peptide stability. Full radiochemical conversion was observed at 
this temperature with no remaining prosthetic group or production of radioactive by-
products.  The product, [18F][Dpr3(octanoyl),Lys19(triazole-ADIBO-F)]ghrelin(1-19) 
[18F]3.12, was isolated by semi-preparative HPLC resulting in good radiochemical yields 
48 
 
of 64-66% of the isolated product in greater than 98% radiochemical purities (Scheme 3.3). 
The SPAAC reaction was performed with quantities less than 200 MBq of the prosthetic 
group, resulting in molar activities of 0.6-0.9 GBq/µmol for the isolated product. 
 
Scheme 3.3 Strain-promoted alkyne-azide cycloaddition of [18F]ADIBO-F prosthetic 
group [18F]3.10 with an azide-modified ghrelin peptide 3.11. Only one regioisomer of 
[18F]3.12 is shown for simplicity. 
A non-radioactive fluorine-19 containing analogue of 3.12 was synthesized to serve as a 
reference standard. Co-injection of the nonradioactive standard 3.12 with the labelled 
peptide [18F]3.12, in addition to an overlay of the UV chromatogram for the standard and 
the radio-chromatogram of the labelled peptide confirms the success of the radiolabelling 
SPAAC reaction (Figure 3.2). Interestingly, the two regioisomers produced had no 
distinguishable difference in retention times, even with various HPLC gradients, reflecting 
the minimal structural difference between these regioisomers. 
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Figure 3.2 Overlaid analytical C18 RP-HPLC chromatograms at 25 to 80% (ACN/H2O, 
0.1% TFA) over 15 minutes of purified peptide [18F]3.12 (solid trace, radio-
chromatogram) and its non-radioactive [19F]3.12 analogue (dashed trace, UV 
chromatogram, λ = 220 nm). 
Using the nonradioactive 3.12, an IC50 of 9.7 nM was obtained from a competitive binding 
assay for the receptor GHSR-1a. This value is comparable to that of similar known ghrelin-
targeting imaging probes (9.5-25.8 nM)24-25 (Figure 3.9) and shows that this peptide 
maintains a strong affinity for the receptor of interest with the addition of our new 
prosthetic group, making it potentially suitable as a cancer-targeting PET imaging probe. 
The stability of the fluorine towards hydrolysis was assessed using a 1 mg/mL solution of 
3.12 in water at 37 °C over 24 h. No degradation of the peptide or fluoride lability was 
observed as indicated by HPLC-MS analysis. 
In a similar manner, [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14) is known to target all 
four of the gastrin-releasing peptide receptor (GRPR) subtypes with sub-nanomolar 
affinities.27 An N-terminal modification of bombesin-targeted peptides does not disrupt 
affinity,28-31 therefore [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14) with an azido-PEG8 
linker on the N-terminus was synthesized and linked to [18F]ADIBO-F in the same process 
as described above resulting in full radiochemical conversion and excellent isolated 
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radiochemical yields for this step of 81-88%. The labelled peptide was purified by semi-
preparative RP-HPLC in greater than 98% radiochemical purities and molar activities of 
0.6-1.1 GBq/µmol. The non-radioactive standard of this peptide was used to validate the 
identity of the labelled peptide by co-injection and for in vitro studies (Chapter 3.4). This 
modified peptide-based imaging agent maintained a high affinity to the GRPR receptor 
with an IC50 value of 0.50 nM, which is comparable to that of the unmodified bombesin 
peptide (0.70 nM) (Figure 3.10).  
Table 3.1 Characterization of the 18F-labelled ghrelin and bombesin peptides. 
Peptide 
[18F][Dpr3(octanoyl),Lys19(triazole-
ADIBO-F)] ghrelin(1-19) 
[18F][D-Phe6,β-
Ala11,Phe13,Nle14]bombesin(6-
14)-PEG8(triazole-ADIBO-F) 
Target 
Receptor 
GHSR-1a GRPR 
IC50[a] (nM) 9.7 0.5 
Azido-Peptide 
Concentration 
(mM) 
3.7 5.6 
Yields[b] (%) 64-66 81-88 
Purities[c] (%) >98 >98 
Molar 
Activities[d] 
(GBq/µmol) 
0.6-0.9 0.6-1.1 
[a] Determined using the 19F standard analogue. [b] Decay-corrected radiochemical yields 
for isolated products. [c] Radiochemical purity by analytical RP-HPLC. [d] Determined by 
analytical HPLC area under the curve (AUC) at 220 nm of an aliquot of the isolated 
fraction. (n=3 for all values)    
3.3 Conclusions 
We have reported a novel ADIBO-F and its tosylate precursor which can be synthesized 
on the side chain of the ADIBO core structure with minimal additional sterics or molecular 
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weight. The tosylate precursor is accessible in a scalable synthetic procedure over eight 
steps in 15% overall yield from inexpensive starting materials via modifications to the 
Popik synthesis. The radiolabelling of the [18F]ADIBO-F precursor was carried out 
efficiently in yields of 21-35% and isolated for use as a prosthetic group in approximately 
an hour from fluoride-18 trapping. The availability of a minimally-sized ADIBO-based 
fluorine-18 prosthetic group in the radiolabelling toolbox allows for copper-free click 
labelling of a wide range of biomolecules and targeting moieties for PET imaging agents.  
As proof-of-principle this prosthetic group’s utility was shown by incorporating it into two 
different cancer-targeting peptides. These reactions were carried out in high yields with 
simple and quick purifications. The entire two-step labelling process can be performed 
manually within two hours including purifications resulting in good molar activities. The 
excellent radiochemical yields of this click reaction in mild, aqueous reaction conditions 
lends itself favourably to the labelling of sensitive biomolecules.  
This novel cyclooctyne prosthetic group demonstrates a new, rapid labelling option for the 
incorporation of fluorine-18 into azide-containing biomolecules to make imaging agents.   
3.4 Experimental 
3.4.1 General Experimental 
All reactions were carried out under a nitrogen atmosphere using oven-dried glassware. 
Dichloromethane (DCM) was distilled over CaH2. Other reagents and solvents were used 
as received from Sigma-Aldrich, Alfa Aesar, or Fisher Scientific. Amino acids and resin 
were received from Peptides International or Chem. Impex.  QMA carbonate SPE 
cartridges were purchased from Waters. [125I]-Ghrelin and [125I]Tyr4-bombesin were 
purchased from Perkin Elmer. Flash chromatography was performed on a Biotage Isolera 
Prime automated flash purification system. Biotage SNAP KP-Sil 10 g, 25 g, or 50 g 
cartridges (45-60 micron) were used with flow rates of 12, 25, and 50 mL/min respectively 
for gradient solvent systems as specified. Fractions were monitored and collected by UV 
absorbance using the internal UV detector set at 254 nm and 280 nm. NMR spectra were 
recorded on a Bruker 400 MHz Spectrometer. Chemical shifts are referenced to the residual 
solvent peaks and recorded in parts per million. ESI HRMS was measured on a Bruker 
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microOTOF 11. EI and CI HRMS was measured on a Thermo Scientific DFS (Double 
Focusing Sector) mass spectrometer. Peptides were purified by preparative reverse-phase 
HPLC-MS and analytical reverse-phase HPLC-MS was performed to assess purities. The 
system consists of a Waters 600 controller, Waters Prep degasser, and Waters Mass Lynx 
software. The UV absorbance was detected using a Waters 2998 Photodiode array detector. 
A preparative column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or 
analytical column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The 
system runs gradients of 0.1% trifluoroacetic acid (TFA) in ACN and 0.1% TFA in water 
at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash. After 
purification, the collected fractions were frozen at -78 °C and lyophilized.  
Cyclotron-produced [18F]fluoride was obtained from Dr. Mike Kovacs at the Cyclotron & 
PET Radiochemistry Facility at St. Joseph’s Hospital in London, Ontario, Canada. 
Analytical radio-RP-HPLC (Agilent RP-C18 column 4.6 x 150 mm, 5 µm) and 
semipreparative RP-HPLC (Agilent RP-C18 column 19 x 150 mm, 5µm) were performed 
on a Waters 1525 Binary HPLC Pump containing a Waters 2487 dual λ absorbance detector 
(292 and 220 nm), Waters InLine degasser, a gamma detector and Breeze software. This 
system runs gradients of 0.1% trifluoroacetic acid (TFA) in ACN and 0.1% TFA in water 
at a flow rate of 1.5 mL/min or 4 mL/min.  
3.4.2 Small Molecule Synthesis 
5H-Dibenzo[a,d]cyclohepten-5-one oxime (3.2) 
Following a literature procedure,23 dibenzosuberenone 3.1 (7.14 g, 34.6 mmol) and 
hydroxylamine hydrochloride (3.60 g, 51.9 mmol) were dissolved in pyridine (30 mL) and 
stirred under reflux for 24 h. The reaction mixture was concentrated under reduced pressure 
and the residue was poured into ice cold 5% HCl (150 mL) and stirred vigorously for 30 
min at 0 °C. The white precipitate was collected by filtration, washed with water, and dried 
in vacuo, yielding oxime 3.2 (7.46 g, 97%) as an off-white powder. 1H NMR (400 MHz, 
CDCl3): δ 9.32 (br s, 1 H), 7.69-7.67 (m, 1 H), 7.62-7.58 (m, 1 H), 7.46-7.34 (m, 6 H), 6.94 
(d, J = 12 Hz, 1 H), 6.90 (d, J = 12 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 156.6, 135.5, 
134.6, 133.8, 130.8, 130.7, 130.5, 129.5, 129.2, 129.1, 129.0, 129.0, 128.9, 127.8, 127.7. 
MS (EI): m/z calculated for C15H11NO : 221.0841; found: 221.0821. 
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Dibenzo[b,f]azocin-6(5H)-one (3.3) 
According to a procedure by Chadwick et al.23 with slight modifications, Eaton’s reagent 
(P2O5/MeSO3H, 20 mL) was added to a flask containing oxime 3.2 (3.00 g, 14.1 mmol). 
The reaction mixture was stirred at 100 °C for 2 h. The reaction was quenched with water 
(65 mL) and extracted into hot EtOAc multiple times. The combined organic layers were 
concentrated under reduced pressure and cooled. The precipitate was filtered (G4 fritted 
filter) and washed with cold EtOAc. The lactam 3.3 (2.63 g, 89%) was obtained as a light 
grey powder. 1H NMR (400 MHz, CDCl3): δ 7.73 (br s, 1 H), 7.47 (dd, J = 7.6, 1.2 Hz, 1 
H), 7.32-7.23 (m, 2 H), 7.22-7.11(m, 4H) 7.05 (dt, J = 7.6, 0.6 Hz, 1 H), 6.96 (d, J = 11.8 
Hz, 1 H), 6.85 (d, J = 11.8 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 173.7, 135.4, 135.3, 
134.8, 134.2, 133.2, 129.8, 129.7, 129.3, 128.5, 128.4, 128.2, 127.8, 127.2, 126.4. HRMS 
(EI): m/z calculated for C15H11NO : 221.0841; found: 221.0849. 
5,6-Dihydrodibenzo[b,f]azocine (3.4) 
From a slight modification to a procedure by Chadwick et al.,23 a dry flask was charged 
with lactam 3.3 (5.00 g, 22.6 mmol) and LiAlH4 (8.58 g, 226 mmol) and flushed with N2. 
Dry Et2O (50 mL) was added slowly and the mixture was subsequently stirred under reflux 
for 12 h. The reaction mixture was cooled at 0 °C, diluted with DCM (100 mL), and 
carefully quenched by the dropwise addition of water. Additional water was added (50 
mL), and the white inorganic precipitate was removed by filtration. The organic layer was 
extracted from water with additional DCM, dried over MgSO4, and concentrated under 
reduced pressure, yielding amine 3.4 (4.25 g, 91%) as a bright yellow solid. 1H NMR (400 
MHz, CDCl3): δ 7.30-7.18 (m, 4 H), 7.00 (dd, J = 7.8, 1.6 Hz, 1 H), 6.91 (m, 1 H), 6.64 
(m, 1 H), 6.56 (d, J = 13.3 Hz, 1 H), 6.47 (dd, J = 8.1, 1.2 Hz, 1 H), 6.38 (d, J = 13.3 Hz, 
1 H), 4.58 (s, 2 H). 13C NMR (100 MHz, CDCl3): δ 147.2, 139.3, 138.2, 134.8, 132.8, 
130.2, 129.0, 128.0, 127.7, 127.4, 121.8, 118.0, 117.8, 49.6. HRMS (EI): m/z calculated 
for C15H13N : 207.1048; found: 207.1056. 
(Z)-2-bromo-1-(dbenzo[b,f]azocin-5(6H)-yl)ethenone (3.5) 
To a solution of amine 3.4 (500 mg, 2.41 mmol) and triethylamine (488 mg, 4.82 mmol) 
in dry DCM (10 mL), bromoacetyl bromide (973 mg, 4.82 mmol) was added dropwise. 
The solution was stirred for 1 h at room temperature. The reaction mixture was diluted with 
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DCM, and washed with 1 M HCl (3x), 2 M NaOH (3x), water and brine. The organic 
fraction was dried over Na2SO4, and concentrated under reduced pressure. The product 3.5 
was obtained as a yellow oil (744 mg, 94%). 1H NMR (400 MHz, CDCl3): δ 7.32-7.26 (m, 
5H), 7.21-7.11 (m, 3H), 6.84 (d, J = 12.9 Hz, 1 H), 6.66 (d, J = 12.6 Hz, 1 H), 5.42 (d, J = 
14.9 Hz, 1 H), 4.32 (d, J = 14.9 Hz, 1 H), 3.58-3.52 (m, 2 H). 13C NMR (100 MHz, CDCl3): 
δ 166.2, 140.0, 136.6, 136.5, 133.8, 133.1, 131.6, 131.2, 130.7, 128.7, 128.7, 128.0, 128.0, 
127.6, 127.5, 55.3, 27.7. HRMS (EI): m/z calculated for C17H14BrNO : 327.0259; found: 
327.0251. 
(Z)-1-(dibenzo[b,f]azocin-5(6H)-yl)-2-hydroxyethanone (3.6) 
A mixture of 3.5 (795 mg, 2.42 mmol) and potassium formate (1.22 g, 14.5 mmol) was 
refluxed in dry methanol for 12 hours. The mixture was diluted with water, extracted into 
DCM, was washed with brine. The organic fraction was dried over Na2SO4, and 
concentrated under reduced pressure. The product was isolated by automated Isolera flash 
column chromatography (SNAP KP-Sil cartridge, 12-100% EtOAc/Hexanes), to yield 
alcohol 3.6 (357 mg, 60%) as a pale yellow amorphous solid. 1H NMR (400 MHz, CDCl3): 
δ 7.32-7.10 (m, 8 H), 6.84 (d, J = 12.6 Hz, 1 H), 6.62 (d, J = 12.6 Hz, 1 H), 5.59 (d, J = 
14.5 Hz, 1 H), 4.37 (d, J = 14.9 Hz, 1 H), 3.84 (d, J = 14.1 Hz, 1 H), 3.43 (d, J = 15.5 Hz, 
1 H), 3.31 (br t, J = 4.3 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 171.7, 137.5, 137.0, 
136.1, 133.5, 133.3, 131.5, 130.6, 130.1, 129.0, 128.8, 128.1, 127.6, 127.4, 127.4, 61.1, 
54.5. HRMS (CI): m/z calculated for C17H16NO2 [M+H]
+ : 266.1176; found: 266.1171. 
Prosthetic group precursor branch 
1-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-hydroxyethanone (3.7)  
A solution of alcohol 3.6 (200 mg, 0.75 mmol) in dry DCM (20 mL) was cooled to 0 °C, 
and bromine (116 µL, 2.26 mmol) was added dropwise. The reaction was stirred for one 
hour at 0 °C and then quenched with sat. aq. Na2SO3. The mixture was extracted into DCM, 
washed with sat. aq. Na2SO3 and brine. The organic fraction was dried over Na2SO4, and 
concentrated under reduced pressure. The product was used without further purification.  
The crude product was dissolved in dry THF (50 mL) and cooled to -40 °C. A solution of 
1 M KOtBu in THF (2.46 mL, 2.46 mmol) was added dropwise and the mixture was stirred 
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at -40 °C for 1.5 h. Another aliquot of KOtBu in THF (0.71 mL, 0.71 mmol) was added 
and the mixture stirred for a further 30 minutes. The mixture was brought to room 
temperature and poured into 100 mL of water. The product was extracted with DCM, and 
the combined organic layers were washed with 1M HCl, water and brine. The organic 
fraction was dried over Na2SO4, and concentrated under reduced pressure. The product was 
isolated by automated Isolera flash column chromatography (SNAP-KP-Sil cartridge, 12-
100% EtOAc/Hexanes), to yield cyclooctyne 3.7 (82 mg, 41%) as an off-white powder. 1H 
NMR (400 MHz, CDCl3): δ 7.71 (d, J = 7.5, 1 H), 7.45-7.28 (m, 7 H), 5.21 (d, J = 14.1 Hz, 
1 H), 4.20 (d, J = 16.0 Hz, 1 H), 3.79 (d, J = 14.1 Hz, 1 H), 3.40 (d, J = 16.0 Hz, 1 H), 2.63 
(br s, 1 H). 13C NMR (100 MHz, CDCl3): δ 172.6 148.8, 147.3, 132.2, 129.2, 128.7, 128.7, 
128.6, 128.3, 127.6, 126.0, 123.2, 123.1, 115.0, 107.3, 60.8, 56.2. HRMS (EI): m/z 
calculated for C17H13NO2 : 263.0946; found: 263.0936. 
2-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-oxoethyl  4-
methylbenzenesulfonate (3.8) 
A solution of cyclooctyne 3.7 (30 mg, 0.11 mmol), tosyl chloride (32 mg, 0.17 mmol), and 
triethylamine (48 µL, 0.33 mmol) in DCM (5 mL) was stirred for 24 hours. The mixture 
was diluted with DCM, washed with 1 M HCl, water, and brine. The organic fraction was 
dried over Na2SO4, and concentrated under reduced pressure to yield tosylate 3.8 (40 mg, 
80%) as an orange solid. The product was stored under a nitrogen atmosphere at -20 °C 
prior to use in radiolabelling. 1H NMR (400 MHz, CDCl3): δ 7.66-7.25 (m, 10 H), 7.21 (d, 
J = 7.9 Hz, 2 H), 5.16 (d, J = 13.9 Hz, 1 H), 4.62 (d, J = 13.9 Hz, 1 H), 4.07 (d, J = 13.9 
Hz, 1 H), 3.67 (d, J = 13.9 Hz, 1 H), 2.39 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 165.0, 
149.4, 147.0, 145.0, 132.7, 132.6, 129.8, 129.2, 128.9, 128.5, 128.4, 128.2, 128.1, 127.7, 
125.8, 123.3, 122.9, 115.3, 107.5, 65.7, 56.0, 21.8. HRMS (EI): m/z calculated for 
C24H19NO4S : 417.1035; found: 417.1031. 
Standard branch 
(Z)-1-(dibenzo[b,f]azocin-5(6H)-yl)-2-fluoroethanone (3.9) 
To a solution of 3.5 (736 mg, 2.25 mmol) in acetonitrile (10 mL), a 1 M solution of TBAF 
in THF (4.50 mL, 4.50 mmol) was added dropwise. The reaction was stirred overnight and 
56 
 
then solvent was removed under reduced pressure. The organic fraction was dissolved in 
DCM, washed repeatedly with water, dried over Na2SO4 and concentrated under reduced 
pressure. The product was isolated by automated Isolera flash column chromatography 
(SNAP-KP-Sil cartridge, 12-100% EtOAc/Hexanes), and 3.9 was obtained as a yellow 
solid (600 mg, quant.).  1H NMR (400 MHz, CDCl3): δ 7.32-7.10 (m, 8 H), 6.86 (d, J = 
12.6 Hz, 1 H), 5.56 (d, J = 14.9 Hz, 1 H), 4.62 (dd, J = 47.4, 13.8 Hz,1 H), 4.32 (d, J = 
15.3, 1 H), 4.31 (dd, J = 46.8, 13.9 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 166.4 (d, 
2JCF 
= 20 Hz), 137.9, 136.8, 136.2, 133.5, 131.4, 130.9, 130.4, 128.9, 128.8, 127.9, 127.6, 127.4, 
127.3, 79.1 (d, 1JCF = 177 Hz), 54.2. HRMS (EI): m/z calculated for C17H14FNO : 267.1059; 
found: 267.1056. 
1-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-fluoroethanone (3.10) 
A solution of 3.9 (600 mg, 2.25 mmol) in dry DCM (40 mL) was cooled to 0 °C, and 
bromine (346 µL, 6.75 mmol) was added dropwise. The reaction was stirred for one hour 
at 0 °C and then quenched with sat. aq. Na2SO3. The mixture was extracted into DCM, 
washed with sat. aq. Na2SO3 and brine. The organic fraction was dried over Na2SO4, and 
concentrated under reduced pressure. The product was used without further purification.  
The crude product was dissolved in dry THF (50 mL) and cooled to -40 °C. A solution of 
1 M KOtBu in THF (7.00 mL, 7.00 mmol) was added dropwise and the mixture was stirred 
at -40 °C for 1.5 h. Another aliquot of KOtBu in THF (2.00 mL, 2.00 mmol) was added 
and the mixture stirred for a further 30 minutes. The mixture was brought to room 
temperature and poured into 100 mL of water. The product was extracted with DCM, and 
the combined organic layers were washed with water and brine. The organic fraction was 
dried over Na2SO4, and concentrated under reduced pressure. The product was isolated by 
automated Isolera flash column chromatography (SNAP-KP-Sil cartridge, 12-100% 
EtOAc/Hexanes), to yield cyclooctyne 3.10 (380 mg, 55%) as a yellow solid. 1H NMR 
(400 MHz, CDCl3): δ 7.72 (d, J = 7.5, 1 H), 7.44-7.26 (m, 7 H), 5.23 (d, J = 13.9 Hz, 1 H), 
4.85 (dd, J = 47.3, 13.5 Hz, 1 H), 4.34 (dd, J = 46.9, 13.5 Hz, 1 H), 3.71 (d, J = 13.9 Hz, 1 
H). 13C NMR (100 MHz, CDCl3): δ 167.1 (d, 
2JCF = 20 Hz), 149.3, 147.1, 132.6, 129.0, 
128.7, 128.6, 128.2, 128.2, 127.6, 125.6, 123.2, 123.0, 115.4, 107.5, 78.9 (d, 1JCF = 177 
Hz), 55.8. HRMS (EI): m/z calculated for C17H12FNO : 265.0903; found: 265.0893. 
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3.4.3 Peptide Synthesis 
Dpr3(alloc),Lys19(N3)-ghrelin(1-19) and (D-Phe
6,β-Ala11,Phe13,Nle14)-Bombesin(6-14) 
peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave 
automated peptide synthesizer. Fmoc-protected Rink amide MBHA resin was used as a 
solid support after swelling in DCM. Fmoc removal was achieved using 40% piperidine in 
dimethylformamide (DMF) over two steps (30 sec and 12 min). Amino acids were coupled 
with 4 equivalents of the Fmoc-protected amino acid, 4 equivalents of HCTU and 8 
equivalents of N,N-diisopropylethylamine (DIPEA) in DMF/N-methyl pyrrolidinone 
(NMP) over 1 hour. Alloc removal was achieved with 24 equivalents of phenylsilane and 
0.1 equivalents of tetrakis(triphenylphosphine) palladium (0) in dry DCM. Octanoic acid 
was manually coupled to the diaminopropionic acid side chain using 3 equivalents of 
octanoic acid, 3 equivalents of HCTU and 6 equivalents of DIPEA in DMF. N3-(PEG)7-
COOH (NovaBioChem) was manually coupled to the N-terminus of (D-Phe
6,β-
Ala11,Phe13,Nle14)-bombesin(6-14) using the above standard coupling conditions.  
Full cleavage of the azido-peptides from resin along with removal of side chain protecting 
groups was achieved with a solution of TFA (95%), triisopropylsilane (TIPS) (2.5%), and 
water (2.5%) over 5 h. The cleaved peptide was precipitated in cold tert-butyl methyl ether 
(TBME) and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide 
dissolved in water, frozen at -78 °C and lyophilized. The azido-peptides were then purified 
by preparative reverse-phase HPLC-MS over a gradient of 30-80% acetonitrile (0.1% 
TFA) in water (0.1% TFA).  The peptides were isolated in >98% purity by analytical RP-
HPLC. 
Dpr3(octanoyl),Lys19(N3)-ghrelin(1-19) (3.11) 
 
HRMS (ESI): m/z calculated for C102H168N36O30 [M + H]
+: 2378.2805; found: 2378.2839.   
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Figure 3.3 Analytical UV chromatogram from RP-HPLC of purified 3.11 (25-80% 
ACN/H2O, 0.1% TFA, 10 minutes, RT = 8.69 min). 
 (D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(N3) 
 
HRMS (ESI): m/z calculated for C79H117N18O21 [M + H]
+: 1653.8641; found: 1653.8605.   
 
Figure 3.4 Analytical UV chromatogram from RP-HPLC of purified (D-Phe6,β-
Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(N3) (30-85% ACN/H2O, 0.1% TFA, 10 
minutes, RT = 9.30 min). 
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Dpr3(octanoyl),Lys19(triazole-ADIBO-F)-ghrelin(1-19)  ([19F]3.12) 
 
Azido-ghrelin peptide 3.11 (10 mg, 3.39 µmol) was dissolved in 1 mL of a 3:2 EtOH/H2O 
solution. ADIBO-F 3.10 (1 mg, 3.77 µmol) was added and the solution was stirred for 5 
hours, diluted with water, frozen and lyophilized. The peptide was purified by preparative 
RP-HPLC, with no difference in retention time between the two regioisomers (25-80% 
ACN/H2O, 0.1% TFA). The non-radioactive fluorine-19 containing ghrelin standard 
[19F]3.12 was obtained (4 mg, 37%, >98% purity by analytical HPLC) as a 5∙TFA salt. One 
regioisomer of 3.12 is shown. HRMS (ESI): m/z calculated for C119H181FN37O31 [M + H]
+: 
2643.3708; found: 2643.3582.  
 
Figure 3.5 Analytical UV chromatogram from RP-HPLC of purified [19F]3.12 (25-80% 
ACN/H2O, 0.1% TFA, 10 minutes, RT = 9.15 min). 
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(D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F) 
 
Azido-bombesin peptide (6 mg, 3.39 µmol) was dissolved in 1 mL of a 3:2 EtOH/H2O 
solution. ADIBO-F 3.10 (1 mg, 3.77 µmol) was added and the solution was stirred for 5 
hours, diluted with water, frozen and lyophilized. The peptide was purified by preparative 
RP-HPLC, with no difference in retention time between the two regioisomers (25-80% 
ACN/H2O, 0.1% TFA). The non-radioactive fluorine-19 containing bombesin standard 
was obtained (2 mg, 30%, >98% purity by analytical HPLC) as a TFA salt.  One 
regioisomer is shown. HRMS (ESI): m/z calculated for C96H129FN19O22 [M + H]
+: 
1918.9544; found: 1918.9551.  
 
Figure 3.6 Analytical UV chromatogram from RP-HPLC of purified (D-Phe6,β-
Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F) (35-80% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 9.22 min). 
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3.4.4 Radiochemistry 
All radiochemical yields are determined for the isolated product and are decay-corrected. 
All radiochemical purities are determined by radio-HPLC analysis of the isolated product.  
Fluorine-18 was trapped on a Waters QMA carbonate SepPak. The activity was eluted into 
a vial with a solution of 2 mg potassium carbonate and 8 mg of kryptofix 222 in 200 µL of 
MilliQ water and 800 µL of ACN.  The solution was evaporated to dryness on a Biotage 
Speed Rotary Evaporator and further dried azeotropically with 1 mL of ACN, repeated 
twice. The dried fluoride-18 was then transferred in two 150 µL washes of ACN to a 
reaction vial containing 1 mg of the tosylate precursor 8. This was allowed to react at 80 
°C for 10 minutes. The crude reaction mixture was then diluted with 300 µL of MilliQ 
water and loaded onto a semi-preparative column (50% ACN/H2O 0.1% TFA). The 
ADIBO-F prosthetic group [18F]3.10 was isolated in 21-35% decay-corrected 
radiochemical yields in greater than 98% purity. The identity of [18F]3.10 was confirmed 
by co-injection with the non-radioactive standard 3.10 showing a consistent retention time 
of 6.5 minutes.  
 
Figure 3.7 Overlaid analytical RP-HPLC UV chromatogram at 220 nm of [19F]3.10 
(dashed) and radio-chromatogram of [18F]3.10 (solid) (50% ACN/H2O 0.1% TFA). 
[18F]ADIBO-F [18F]3.10 collected semi-preparatively was dried on a Biotage Speed Rotary 
Evaporator. To this vial, 2 mg of either Dpr3(octanoyl)Lys19(N3)-ghrelin(1-19) (3.11) or 
(D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14)-PEG8(N3) in 200 µL of a 1:1 solution of 
MilliQ water and ACN was added. This was heated at 70 °C for 15 minutes. The crude 
reaction mixture was diluted with 300 µL of MilliQ water and loaded onto a 
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semipreparative column (25 to 80% ACN/H2O, 0.1% TFA) In either case, retention time 
between regioisomers was indistinguishable. The labelled peptides were isolated in 64-
66% ([18F]3.12) or 81-88% decay-corrected radiochemical yields, respectively, with 
greater than 98% radiochemical purity. Their identities were confirmed by analytical 
HPLC co-injection with their nonradioactive analogues with consistent retention times at 
4.5 or 6.6 minutes, respectively.  
 
Figure 3.8 Overlaid analytical RP-HPLC UV chromatogram at 220 nm of standard (D-
Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F) (dashed) and radio-
chromatogram of [18F](D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-
ADIBO-F) (solid) (25 to 80% ACN/H2O, 0.1% TFA). 
Molar activities for the isolated labelled peptides were determined based on the area under 
the curve (AUC) for the UV absorption at 220 nm. A calibration curve for each peptide 
was constructed from varying concentrations of the nonradioactive analogue (R2>0.99). 
For the ghrelin peptide, 10 µL of 0.0125-0.5 mg/mL solutions of [19F]3.12 were injected 
onto an analytical column running a gradient of 25 to 80% (ACN/H2O, 0.1% TFA) over 
15 minutes. For the bombesin peptide, 10 µL of 0.0125-0.1 mg/mL solutions were injected 
onto an analytical column running a gradient of 25 to 80% (ACN/H2O, 0.1% TFA) over 
15 minutes. Molar activities for the isolated labelled peptides were then determined from 
the total activity collected and volume of the fraction collected semipreparatively, and the 
AUC for a 10 µL aliquot of the collected fraction run on the same gradient. This gave rise 
to molar activities of 0.6-0.9 GBq/µmol for [18F]3.12, and 0.6-1.1 GBq/µmol for the 
labelled bombesin peptide.  
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3.4.5 In Vitro Competitive Binding Assays 
GHSR-1a  
In vitro GHSR-1a affinity for [19F]3.12 was determined through a competitive binding 
assay using HEK293 cells transiently transfected to express GHSR-1a and [125I]Ghrelin as 
the GHSR-1a-specific radioligand. The compound of interest (30 µL, at concentrations 
ranging from 10-11 to 10-5 M) and 15,000 cpm of [125I]Ghrelin were mixed with the binding 
buffer (25 mM HEPES, 0.4% BSA, 5 mM MgCl2, 1 mM CaCl2, 1 mM EDTA in H2O, pH 
7.4) in 1.5 mL Eppendorf vials. A suspension of 50,000 HEK293 cells in 50 µL binding 
buffer was added to each vial to give a final volume of 300 µL.  
GRPR 
In vitro GRPR affinity for the standard (D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14) and 
(D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14)PEG8(triazole-ADIBO-F) was determined 
through a competitive binding assay using PC-3 cells and [125I]Tyr4-Bombesin as the 
GRPR-specific radioligand. PC-3 cells were grown in Ham’s F-12K medium 
supplemented with 10% fetal bovine serum. The compound of interest (30 µL, at 
concentrations ranging from 10-12 to 10-5 M) and 20,000 cpm of [125I]Tyr4-Bombesin were 
mixed with the binding buffer (25 mM HEPES, 0.4% BSA, 5 mM MgCl2, 1 mM CaCl2, 1 
mM EDTA in H2O, pH 7.4) in 1.5 mL Eppendorf vials. A suspension of 500,000 PC-3 
cells in 50 µL binding buffer was added to each vial to give a final volume of 300 µL.  
In each binding assay the vials were shaken at 550 rpm for 20 minutes at 37 °C. 
Immediately after the incubation, the vials were centrifuged at 13,000 xg, and the 
supernatant removed. The cell pellet was washed with 500 µL of 50 mM Tris buffer (pH 
7.4), centrifuged again, and the supernatant was removed. The amount of [125I]-radioligand 
bound to the cells was measured using a gamma counter (Perkin-Elmer). IC50 values were 
determined by nonlinear regression analysis to fit a 4-parameter dose response curve using 
GraphPad Prism (Version 6.0c). All data points were obtained in triplicate. IC50 values 
were as follows: [19F]3.12, 9.7 nM; (D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-
14)PEG8(triazole-ADIBO-F), 0.50 nM; and (D-Phe
6,β-Ala11,Phe13,Nle14)-bombesin(6-14), 
0.70 nM.  
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Figure 3.9 Binding curve for the competitive binding assay of [19F]3.12 in HEK293-
GHSR-1a cells. The IC50 value determined was 9.7 nM. 
 
Figure 3.10 Binding curves for the competitive binding assay of standard (D-Phe6,β-
Ala11,Phe13,Nle14)-bombesin(6-14) (red), and of (D-Phe6,β-Ala11,Phe13,Nle14)-
bombesin(6-14)PEG8(triazole-ADIBO-F) (black) with PC3 cells. The IC50 values 
determined were 0.70 and 0.50 nM, respectively. 
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Chapter 4  
4 Synthesis and Screening of a Combinatorial Library of 
Fluorine-Integrated Peptides for PET Imaging Agent 
Discovery 
4.1 Introduction 
Advances in the fields involving molecular imaging are increasingly allowing for non-
invasive imaging of biological processes and markers related to a variety of disease states. 
Imaging of specific targets can aid in diagnosis and staging of disease, as well as predicting 
and monitoring response to targeted treatment. This is an especially advantageous tool with 
the advent of personalized medicine wherein knowledge of the presence of specific 
biomarkers can determine course of treatment. For imaging modalities such as positron 
emission tomography (PET), the scope and progression of its clinical relevance depends 
on the development of new radiopharmaceutical agents towards an expanding variety of 
targets. 
Peptides are especially useful as the targeting ligand component of PET 
radiopharmaceuticals because they are easy to synthesize and modify, have biological half-
lives that match those of the radioisotopes used, and often have high specificity and 
selectivity towards their target.1  Peptide radiopharmaceuticals can be constructed through 
rational design or discovered through screening campaigns of libraries of compounds. In 
the former, the radiopharmaceutical is designed by modifying a known ligand of the target 
or designing a peptide based on the microenvironment of the target. In contrast, screening 
campaigns can be undertaken which lead to the discovery of new targeting ligands, which 
is impactful when the target is unknown, there are no known ligands for a target, or those 
that exist do not have an appropriate pharmacokinetic profile for imaging. Common 
methods include high-throughput screening (HTS) of compound libraries, in silico 
screening of libraries, or screening of combinatorial libraries such as one-bead one-
compound (OBOC) or phage display.  
The synthesis of OBOC libraries through a split-and-mix approach creates libraries of 
millions of unique peptides on-resin, where each resin bead hosts multiple copies of a 
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single random peptide sequence.2 Screening these beads against targets of interest has 
resulted in the successful identification of peptides targeting cancer biomarkers and other 
disease states.3–7 Unfortunately, peptides discovered from these libraries have only rarely 
been converted into imaging agents, as appending an imaging moiety often leads to a 
decrease in the target affinity observed during the library screen.8–15 An OBOC library is a 
useful combinatorial approach in that they are synthesized via solid-phase peptide synthesis 
(SPPS), and unnatural peptide modifications are trivial to include. Surprisingly, only a few 
descriptions exist where an imaging component was included in the synthesis of an OBOC 
library; in all cases, the imaging moiety was appended to a terminal of the peptides or 
peptoids.16–18 Screening of an imaging agent library would allow for the discovery of new 
radiopharmaceutical imaging agents where the imaging moiety is already accounted for in 
target binding.  
Bioconjugation through click chemistry is a popular technique for radiolabelling of PET 
imaging agents because of its fast reaction kinetics, physiologically friendly reaction 
conditions and significantly reduced byproducts.19 A  particularly interesting click reaction 
is the strain-promoted alkyne-azide cycloaddition (SPAAC) which is a substitute for 
traditional copper-catalyzed click chemistry reactions using strained cyclooctynes, 
avoiding the use of cytotoxic copper and its consequential removal thereafter.20–22  
As stated previously, there is a need for new receptor-targeted PET agents, and a recent 
exciting target is the CXCR4 chemokine receptor that has been implicated in over 23 types 
of cancer.23 CXCR4 has only two known endogenous ligands, SDF-1α (also known as 
CXCL12) and ubiquitin.24 Together CXCR4 and SDF-1α are known to have roles in 
chemotactic and angiogenic pathways, which corresponds to the expression of CXCR4 in 
metastatic cancers. While CXCR4 is normally expressed in bone marrow, the spleen, 
thymus, lymph nodes, pituitary gland, and adrenal glands at low rates, its expression is 
significantly higher in malignant tissue compared to healthy adjacent tissues. These aspects 
make it an interesting target for imaging of CXCR4-expressing cancers.25 Current peptide-
based radiopharmaceutical imaging agents for CXCR4 were all developed from 
polyphemusin II, an antimicrobial peptide found in horseshoe crab extracts (Tachypleus 
tridentatus). Structure-activity studies and truncation of this peptide resulted in T140, a 14 
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amino acid peptide with a single disulfide bond with nanomolar affinity for CXCR4.26,27 
Radiolabelling of T140 with fluorine-18 has been performed on the N-terminus or the Lys7 
side chain with various prosthetic groups. In many cases, non-CXCR4 specific binding to 
red blood cells or significant liver and kidney uptake was observed which limits their utility 
as targeted imaging agents.28–30 A novel cyclic pentapeptide, FC131, was derived from the 
most important binding residues of T140.31 It has been modified to contain a DOTA 
chelator, which has been radiolabelled with 68Ga (Pentixafor), and is now being explored 
as a tool to image a variety of CXCR4-expressing cancers in humans.32–34 In the 
development of a fluorine-18 version of FC131, the ligand was radiolabelled via a click 
reaction on a side chain, but has not yet been explored for in vivo biodistribution or 
imaging.35 Unsurprisingly, due to the rational design approach in which all the peptides 
were all derived from the same starting peptide, they have similar biodistribution properties 
in vivo. The use of combinatorial libraries could lead to the discovery of imaging agents 
targeting CXCR4 with a different pharmacokinetic profile (Chapter 2).  
Herein, we describe an OBOC library in which fluorine has been randomly inserted within 
the peptide side chains. The use of converging and diverging pools during synthesis allows 
for the imaging component to be included exactly once in each peptide sequence. The 
imaging component is distributed evenly among the eight positions in the octamer peptides; 
the remaining seven amino acids are randomized using fifteen different natural amino 
acids. Screening of the library against the target CXCR4 will thus result in the discovery 
of peptides where the imaging component is included in ligand-target interactions. Notably, 
the fluorine has been incorporated into the peptide structure through a SPAAC reaction 
using the non-radioactive standard of a recently reported fluorine-18 prosthetic group.36 
This design allows for hits from the library to be simply and directly translated into their 
fluorine-18 counterpart for PET imaging.  
4.2 Results and Discussion 
4.2.1 Library Design 
Although high-throughput techniques such as combinatorial OBOC libraries are effective 
at identifying potential ligands for receptor targeting, these technologies are rarely adapted 
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into the discovery of complete imaging agents.16-18 By incorporating an imaging 
component directly into such a library, screening for target affinity will involve the entire 
imaging agent and no major post-screening modifications should be necessary. Our library 
design sought to integrate the imaging entity within the peptide structure, rather than 
simply appending the imaging component onto one of the peptide termini away from 
potential binding interactions. We chose to design a library of potential PET imaging 
agents, using a non-radioactive surrogate containing fluorine-19. Fluorine-19 takes the 
place of fluorine-18, which is an important radioisotope commonly used in PET imaging 
due to its half-life (~ 110 min), high abundance of positron decay and availability from 
cyclotrons. In addition, fluorine-18 can be incorporated into biomolecules via carbon-
fluorine bonds, which has decreased bulk and increased in vivo stability compared to some 
other radiolabels. We chose to use copper-free click chemistry for simple translation of our 
hit peptides into imaging agents for PET imaging using SPAAC radiolabelling. We 
developed a relatively small fluorine-containing azadibenzocyclooctyne (ADIBO-F) that 
can be radiolabelled with fluorine-18 and incorporated into an azide-containing amino acid 
side chain to produce a cyclooctatrizaole-fluorine-containing residue.36 Fmoc-protected 
azide-containing amino acids such lysine azide are widely available commercially and 
therefore amenable to including in the SPPS of an OBOC library (Figure 4.1). 
 
Figure 4.1 Incorporation of an 18/19F-ADIBO-F into a lysine-azide residue in a peptide. 
Although amino acids in an OBOC library are traditionally incorporated equally at each 
coupling step, including a lysine azide in such a way could result in peptides in the library 
containing multiple or, more likely, zero azide functional groups, and subsequently 
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multiple or zero locations of the fluorine imaging component. Unfortunately, hits such as 
these would limit the utility of the library, as hits may have to be modified to include an 
imaging component after all. We decided to design an octamer library that included setting 
the location of the lysine azide at each of the eight residue positions. Instead of creating 
and screening eight separate libraries, we chose to design a two-pool technique that would 
allow for the synthesis of these eight “mini-libraries” at once (Figure 4.2). In brief, at each 
coupling step, one eighth of the initial library mass is diverted from the original pool to the 
lysine azide pool to ensure even distribution of the imaging component through the eight 
residue locations. Initially, one eighth of the library pool is separated and coupled to lysine 
azide. After coupling with lysine azide the beads are placed into a separate “lysine azide” 
pool (Figure 4.2, top cascade, pool 2). The remaining seven eighths of the library in the 
original pool (Figure 4.2, bottom cascade, pool 1) undergo a traditional split-and-mix step 
with n natural amino acids in n wells. All beads are combined in their respective separate 
pools for Fmoc deprotection and mixing between coupling steps. For the second coupling 
step, another eighth of the initial library size is separated from pool 1 and coupled to lysine 
azide. All remaining beads in both pools 1 and 2 undergo traditional split-and-mix steps in 
their respective pools. The newly azide-containing peptides are then added to the rest of 
the dipeptides in pool 2. This process continues for eight coupling, mixing and deprotection 
steps where resin switches pools after azide incorporation to ensure only a single azide is 
present in each library bead sequence. After eight coupling cycles, the resin is all in pool 
2. At this point, each peptide in the library contains a single azide and can be conjugated 
to our non-radioactive ADIBO-F prosthetic group surrogate to incorporate an imaging 
moiety into the entire library. By using 15 amino acids for the split-and-mix steps, the 
theoretical library diversity is around 1.37 billion unique amino acid sequences (= 8 x 157). 
In 1.5 million beads, there is only around 0.1 % of the potential sequences expressed, and 
thus no redundancy is likely. Therefore, the result of this synthesis cascade is a library of 
approximately 1.5 million potential peptide-based imaging agents that should each express 
a different peptide sequence and contain a single imaging moiety. 
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Figure 4.2 Synthesis cascade showing two-pool split-and-mix SPPS steps to incorporate 
a lysine-azide into a library of octapeptides in single random position. This allows a 
fluorine-containing cyclooctyne (ADIBO-F) to be globally clicked to the library to 
produce a library of on-bead imaging agents. 
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4.2.2 Library Synthesis 
The library was synthesized on one gram of amine-functionalized Tentagel resin (~1.5 
million beads), due to its loading, amenability to aqueous solvents, and uniform size of 
beads. All peptides were linked to the resin beads using a photocleavable linker ((3‐amino‐
3‐(2‐nitro‐phenyl)propionic acid) (ANP)) and library synthesis and screening was 
performed in the dark. This linker allows the peptides to stay attached to the bead during 
side chain deprotection, while also allowing for cleavage from the hit beads under UV light 
for peptide sequence determination. The library was then synthesized using SPPS using 
the synthesis cascade as described above (Figure 4.2). Fifteen natural Fmoc-amino acids 
were used excluding those that would complicate sequencing by tandem mass spectrometry 
(MS/MS): tryptophan, cysteine, and methionine due to their tendency to oxidize; as well 
as leucine and glutamine because they are isobaric with isoleucine and lysine. All library 
beads were combined at the end, swelled in an acetonitrile/water mixture and 1.5 
equivalents of ADIBO-F was added to afford the library of globally clicked products with 
a lysine(cyclooctatriazole-F) residue. Side chain protecting groups were removed with a 
cocktail of 95% trifluoracetic acid (TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water 
and the resin was washed thoroughly. To confirm complete library synthesis on-resin, eight 
beads were analyzed by MALDI MS/MS. Since there is an amide bond in the ADIBO 
prosthetic group, a m/z ratio of the peptide parent mass minus 61 Da was observed in all 
MS/MS spectra. This corresponds to the m/z of the entire peptide missing the 2-
fluoroacetyl radical fragment of the cyclooctatriazole-F and confirming that the peptides 
indeed each contained a clicked triazole component (Figure 4.3). 
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Figure 4.3 Sample MS and MS/MS spectra demonstrating presence of an ion fragment 
resulting from loss of 61 Da from the parent peptide m/z to confirm inclusion of imaging 
component cyclooctatriazole-F. 
4.2.3 On-Bead Two-Colour Screen 
The imaging agent library was screened by employing a two-colour method wherein the 
bead-hosted peptides can be screened for both affinity and selectivity to the target in a 
single step.37 As CXCR4 was the target of choice due to its implication in over 23 cancer 
types, the cell lines utilized were U87.CD4.CXCR4 as a positive cell line that is transfected 
to overexpress the receptor of interest, and U87.CD4 as a control cell line that lacks this 
transfection.38 To aid in visualization by fluorescence microscopy, U87.CD4.CXCR4 or 
U87.CD4 cells were preincubated with a CellTracker dye (ThermoFisher), Green CMFDA 
or Red CMTPX, respectively.  In stages, the library was incubated in multiple 6-well plates 
at concentrations of ~10,000 beads/well and 200,000 cells/well of each cell line in a total 
of 3 mL of serum-free DMEM media. The plates were shaken gently for 1 hour at 37 °C, 
at which point receptor-peptide interactions between the cells and beads were fixed with 
4% paraformaldehyde. To stop cross-linking, glycine was added to each well, and the entire 
library was then combined and rinsed with water and resuspended in phosphate-buffered 
saline (PBS). The library was visualized by confocal fluorescence microscopy and 25 beads 
that displayed binding with only green fluorescent cells (dye λex/em = 492/517 nm) and not 
red fluorescent cells (dye λex/em = 577/602 nm) were manually isolated as CXCR4-selective 
hits for further investigation (Figure 4.4). Although hundreds of suitable hit beads were 
observed, only 25 beads which appeared to have high affinity to the target were chosen 
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from this screening to ease the bottleneck step of manual de novo sequencing to follow. 
The beads were rinsed with ethanol to remove bound cells, and then placed into individual 
wells of a 96 well plate. These hit beads were swollen in methanol and placed under a 
160 W 365 nm UV lamp for 1.5 hours to afford photolysis of peptides from the beads. 
Photocleavage of the o-nitrophenyl ANP linker results in a carboxamide at the C-
terminal.39 The supernatant was then subjected to MALDI MS/MS for peptide sequence 
deconvolution.  
 
Figure 4.4 Representative confocal fluorescence microscopy images of library Tentagel 
beads during two-colour screening depicting A) bulk beads B) isolated beads showing 
affinity for CXCR4 C) individual bead showing specificity to CXCR4. 
4.2.4 MALDI MS/MS De Novo Sequencing of Hits 
MALDI MS/MS was chosen as a method of hit deconvolution due its high sensitivity and 
because of the cost-effectiveness for sequencing multiple peptide hits. MALDI was 
performed using α-cyano-4-hydroxycinnamic acid (CHCA) as the matrix, the highest 
intensity peaks were chosen as the parent MS and fragmented to produce MS/MS spectra 
for each peptide. Peptides predictably fragment through the polyamide backbone in a 
collision cell, which allows for comparison of mass differences between ion peaks to 
masses of amino acid residues to determine peptide sequences (Figure 4.5).40 Of the 25 
peptides, six showed no MS ion in the mass range of interest for our library constructs 
(~1000-1500 Da) (Figure 4.8). Of the remaining, eight sequences (4.1-4.8) were fully 
deconvoluted by manual de novo sequencing (Table 4.1). 
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Figure 4.5 MALDI MS/MS deconvolution of hit peptide imaging agent 4.3 showing a 
full y series of ions and some b series ions. 
Table 4.1 Sequences and IC50 values of hit peptide structures as determined by de novo 
MS/MS sequencing. Where X = lysine(cyclooctatriazole-F). Peptides have a free N-
terminus and an amidated C-terminus. 
NUMBER SEQUENCE IC50 (µM) 
4.1 H- E R R H S Y H X -NH2 28 
4.2 H- F A R Y P A S X -NH2 86 
4.3 H- G Y S E E H G X -NH2 109 
4.4 H- A I F H E R V X -NH2 ≈ 700 
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4.5 H- N P R N I E R X -NH2 ≈ 700 
4.6 H- N F A H V I X D -NH2 >1000 
4.7 H- T N D X N H I G -NH2 >1000 
4.8 H- K N H P V P G X -NH2 >1000 
A sequencing success rate of 42% is not unreasonable for this technique. Incomplete and 
non-uniform fragmentation within the peptide backbone limits success and is a known 
drawback to this sequencing approach. Complete fragmentation has been described as “a 
modern form of surrealism.”41–43 Although databases exist to perform de novo sequencing 
of natural peptides, peptides including unnatural amino acids such as the 
lysine(cyclooctatriazole-F) moiety in our library require additional input and result in 
lengthy and unreliable automated sequencing. It is apparent that a disproportional number 
of solvable hit sequences contain the lysine(cyclooctatriazole-F) residue close to or at the 
C-terminus of the peptide. This bias likely exists for two reasons. First, sequences with the 
bulky cyclooctyne may not be favourable for binding to this particular target, resulting in 
hits where this residue is placed close to the bead and is less likely to project into a binding 
pocket of the CXCR4 receptor. Secondly, peptide sequences where the high mass residue 
is at an end of the peptide appears to result in more complete fragmentation during MS/MS, 
which can be partially attributed to better detection capability of ions in the middle of the 
mass range analyzed (Figure 4.6). Peptide sequences (4.1-4.8) as determined from MALDI 
MS/MS sequencing were re-synthesized on Rink amide resin and purified as their C-
terminal amides and once again subjected to MALDI MS/MS at higher (micromolar) 
concentrations. MS/MS spectra were compared to those from the library hit bead for 
confirmation of accurate structure determination.   
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Figure 4.6 MALDI MS/MS showing insufficient fragmentation to deconvolute entire 
peptide sequence when the Lys(cyclooctatriazole) residue is centered in the peptide 
sequence. 
4.2.5 CXCR4 Affinity Determination of Hit Peptides 
Re-synthesized, purified peptides were then further tested for affinity by means of in-
solution in vitro binding assays. Eight peptide sequences (4.1-4.8) were tested using a 
competitive radioligand binding assay with U87.CD4.CXCR4 cells and [125I]-SDF-1α as 
the radioligand. Binding affinities towards the receptor were determined as IC50 values that 
ranged from 28 µM to the mM range (Table 4.1).  Three peptides were observed to have 
micromolar affinity for the target, while others required millimolar concentrations before 
any displacement of the 125I-ligand was observed. This was an encouraging result as 
screening of non-focused libraries typically results in hits with micromolar affinities to the 
target, which are then subjected to further lead optimization. Importantly, our three hits 
were found to have micromolar affinity to CXCR4 from our combinatorial library of 1.5 
million random peptide sequences that include a fluorine moiety. Therefore, further lead 
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optimization could be based on straightforward modifications to the peptide sequence and 
optimizing in vivo stability, instead of focusing on incorporating an imaging component 
without concomitant loss of receptor affinity. Furthermore, we believe that peptide hits 
with on-bead CXCR4 affinity yet displaying no or poor affinity to the target based upon 
the competitive binding assay, could instead be binding allosterically to the receptor and 
would require other methods to reconfirm and evaluate their affinity. Nonetheless, peptide 
hits 4.1-4.3 serve as a starting point to continue structure-activity relationship studies to 
further optimize new fluorine-containing peptides as CXCR4-binders for PET imaging. 
Importantly, peptide 4.3 is particularly interesting; although it does not have the highest 
affinity of those studied, it maintains micromolar affinity with only one basic residue and 
two acidic residues. Most previously identified CXCR4-binding peptides and small 
molecules are highly positively charged due to the negatively charged surface of the 
CXCR4 binding pocket,44,45 so this peptide structure presents potential for a new CXCR4 
ligand with a unique binding mode and different overall physicochemical properties.  
4.3 Conclusions 
A unique combinatorial library of fluorine-containing peptides was synthesized using an 
OBOC two-pool approach to insert a single imaging component randomly into each 
peptide sequence in the library. This library was used to discover potential PET imaging 
agents for CXCR4. Three new peptide imaging agents with micromolar affinity and 
selectivity to CXCR4 were discovered as initial hits in a single step two-colour library 
screen and can undergo lead optimization to improve their CXCR4 affinity. Subsequently, 
they can be easily translated into cancer imaging probes by replacing the 19F-moiety in 
each hit by labelling the azido-peptides with our established 18F-labelled prosthetic group. 
This labelling can be performed in high radiochemical yields and purities due to the nature 
of the click reaction. The bottleneck step in hit identification from this library is due to the 
laborious and inconsistent process of manual de novo sequencing by MS/MS. Fortunately, 
recent advances in OBOC technologies are beginning to ease these challenges,46,47 and our 
application could be combined with these new technologies for high-throughput 
implementation. This novel type of OBOC library can be used to screen against various 
targets to discover new 18F-based PET imaging agents. In addition, any appropriate alkyne-
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based imaging moiety could be clicked into such libraries at the lysine-azide residue to 
afford OBOC libraries for a wide variety of imaging applications. 
4.4 Experimental 
4.4.1 General Experimental 
All reagents and solvents were used as received from Sigma-Aldrich, Alfa Aesar, or Fisher 
Scientific. Amino acids and resins were received from Peptides International or Chem. 
Impex.. ADIBO-F was prepared as previously described.36 Peptides were purified by 
preparative reverse-phase HPLC-MS and analytical reverse-phase HPLC-MS was 
performed to assess purities. The system consists of a Waters 600 controller, Waters Prep 
degasser, Waters Quattro micro Mass, and Waters Mass Lynx software. The UV 
absorbance was detected using a Waters 2998 Photodiode array detector. A preparative 
column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or analytical 
column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The solvent 
system runs gradients of 0.1 % trifluoroacetic acid (TFA) in ACN and 0.1 % TFA in water 
at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash. After 
purification, the collected fractions were frozen at -78 °C and lyophilized. ESI HRMS was 
measured on a Bruker microTOF 11. 
4.4.2 OBOC Library Synthesis 
The library was synthesized using a split-and-mix approach with standard Fmoc solid 
phase peptide synthesis (SPPS) conditions on a Biotage SyroWave automated peptide 
synthesizer combined with manual peptide coupling steps. Due to the photolabile linker, 
synthesis was performed in the dark. Briefly, 1 g of Tentagel S-NH2 resin (90 µm, 0.26 
meq/g) was swelled in DCM and manually coupled to Fmoc-ANP-OH linker (4 eq) using 
HCTU (4 eq) and N,N-diisopropylethylamine (DIPEA) (8 eq) in DMF for two hours. 
Automated Fmoc removal was achieved using 40% piperidine in dimethylformamide 
(DMF) over two steps (30 sec and 12 min). The following synthesis cascade approach 
follows Figure 4.2. Initially, one eighth of the library was separated (0.0325 mmol) and the 
remaining resin was split evenly into fifteen synthesizer vessels. To the 0.0325 mmol of 
resin, Fmoc-Lys(N3)-OH was manually coupled (0.13 mmol, 4 eq) with HCTU (4 eq) and 
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DIPEA (8 eq) for 2 hours.  To the fifteen wells, resin in each well was coupled to a different 
Fmoc-amino acid (4 eq) (all natural L-amino acids excluding tryptophan, cysteine, 
methionine, leucine and glutamine) using HCTU (4 eq) and DIPEA (8 eq) in DMF for 1.5 
hours, followed by automated Fmoc removal and recombination of the resin. Another 
0.0325 mmol of resin was separated from this pool, coupled to Fmoc-Lys(N3)-OH as 
above, and the rest was split evenly into fifteen synthesizer vessels again. After each 
coupling cycle/Fmoc removal cycle, the resin was recombined into one pool, 0.0325 mmol 
removed and manually coupled to Fmoc-Lys(N3)-OH and the remainder divided into 
fifteen vessels again (until there was no remaining pool). This was repeated eight times to 
afford peptides of 1-8 amino acids in length where the Lys(N3) is the N-terminal amino 
acid in each separated 0.0325 mmol portion. To finish the synthesis of the peptides as 
octamers in length, the initial 0.0325 mmol portion coupled to Lys(N3) was split evenly 
into fifteen synthesizer vessels, and resin in each was coupled to a different Fmoc-amino 
acid (4 eq) using HCTU (4 eq) and DIPEA (8 eq) in DMF for 1.5 hours. This was followed 
by automated Fmoc removal and recombination of the resin, at which point the next 0.0325 
mmol azide-containing portion of appropriate peptide length was added to this pool. This 
coupling/Fmoc removal cycle was repeated until all peptides were eight amino acids in 
length. All library resin was the combined, and ADIBO-F (1.5 eq) was added in a 60:40 
ACN/H2O mixture (10 mL) and shaken for 2 hours. The resin was rinsed with DCM (x6). 
Full side-chain deprotection was afforded with 95% TFA, 2.5% triisopropylsilane and 
2.5% water for 5 hours (20 mL). The library was rinsed thoroughly with DCM, 5% 
DIPEA/DMF, DMF, DCM, MeOH, H2O, EtOH, and stored in 70% EtOH/H2O.  
4.4.3 Cell Culture 
U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R. 
Littman. U87.CD4.CXCR4 cells were maintained in DMEM – high glucose (Sigma) 
containing 15% fetal bovine serum (FBS), 1 μg mL-1 puromycin, 300 μg mL−1 G418, and 
1× penicillin–streptomycin. U87.CD4 cells were maintained in DMEM – high glucose 
(Sigma) containing 10% FBS, 300 μg mL−1 G418, and 1× penicillin–streptomycin. All cell 
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lines were cultured at 37 °C in humidified atmosphere with 5% CO2 and passaged 2 to 3 
times per week. 
4.4.4 On-Bead Two-Colour Fluorescent Screening 
U87.CD4.CXCR4 cells or U87.CD4 cells at 80% confluency were incubated with 5 µM 
CellTracker™ Green CMFDA Dye (ThermoFisher) or 5 µM CellTracker™ Red CMTPX 
Dye (ThermoFisher) in serum-free DMEM media for 30 min at 37 °C. Dye was aspirated, 
and cells were lifted using an enzyme-free dissociation solution (Sigma). Cells were 
counted and resuspended in serum-free DMEM at 200,000 cells/mL. Library beads were 
suspended in Dulbecco’s modified eagle medium (DMEM) and dispersed in non-treated 
6-well plates at ~20 mg/10,000 beads/well (entire library is ~1.5 million beads). Cells from 
each cell suspension were added to each well (1 mL, 200,000 cells each) and total volumes 
were brought up to 3 mL with DMEM. Plates were shaken at 550 rpm for 1 hour at 37 °C. 
To each well, 0.33 mL of 37% paraformaldehyde was added for a final concentration of 
4%. Fixing was quenched after ten minutes by the addition of 2 M glycine to a final 
concentration of 20%. The entire library of beads was recombined and rinsed with water 
and phosphate buffered saline (PBS) repeatedly then suspended in PBS. The library beads 
were dispersed in culture dishes for visualization by fluorescence microscopy. Confocal 
fluorescence microscopy was performed on a Nikon A1R Confocal Laser Microscope with 
either a 488 nm laser for green fluorescence excitation and the emission range set to 500-
550 nm and a 561 nm laser for red fluorescence with the emission collected at 600-660 nm. 
Beads showing high levels of interactions with only green fluorescent U87.CD4.CXCR4 
cells were manually isolated using a micropipette and placed in individual wells of a 96-
well plate. Beads were then carefully washed multiple times with 95% ethanol to remove 
bound cells and visualized to confirm removal of cells.  
4.4.5 Photocleavage and MALDI MS/MS 
To confirm library synthesis, eight beads were placed in individual wells of a 96 well plate, 
swollen in methanol, and placed under a 160 W 365 nm lamp for 1.5 hours to afford 
photolysis from the resin. The single bead peptide solutions were approximately nanomolar 
in concentration based on <10% cleavage from the 0.26 mmol/g loading of an individual 
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bead. MALDI MS/MS was obtained for the highest intensity MS peak and de novo 
sequencing was performed to identify peptide sequences. 
 
Figure 4.7 Sample de novo sequencing of a random library peptide of 1177 Da showing 
almost complete coverage of b and y ion series. 
Twenty-five individual hit beads from the library screen were suspended in 40 µL of 
methanol in individual wells of 96-well plates and placed under UV light (160 W, 365 nm) 
for 1.5 hours to achieve <10% cleavage from the bead due to the ANP linker. Conversely, 
1 mg/mL solutions of purified peptides 4.1-4.3 in acetonitrile were prepared. The solutions 
were then mixed with equal parts matrix α-cyano-4-hydroxycinnamic acid (CHCA) in 
acetonitrile and placed onto the MALDI target. MALDI TOF/TOF was performed on an 
AB Sciex TOF/TOF 5800 by the facility manager of the MALDI Mass Spectrometry 
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Facility at the London Regional Proteomics Centre. Mass spectra were obtained and 
analyzed for each sample (Figure 4.8). The highest intensity peak in each MS spectra was 
subjected to MS/MS analysis and peptide sequences were deconvoluted manually by 
examining mass differences between fragment ions in these spectra (Chapter 6 Appendix).  
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Figure 4.8 MALDI mass spectra for hit peptides demonstrating A) MS with no ions present 
in the mass range of interest for our library, B) MS with multiple ion peaks, and C) MS 
with a single parent ion present (and its sodium adduct). 
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4.4.6 Hit Peptide Synthesis and Characterization 
Peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave 
automated peptide synthesizer. Fmoc-protected Rink amide MBHA resin was used as a 
solid support after swelling in DCM. Fmoc removal was achieved using 40% piperidine in 
DMF over two steps (30 sec and 12 min). Amino acids were coupled with the Fmoc-
protected amino acid (4 eq), HCTU (4 eq) and DIPEA (8 eq) in DMF/N-methyl 
pyrrolidinone (NMP) over 1 hour. For the clicked peptide analogues 4.1-4.8, ADIBO-F 
(1.5 eq) was then added in DCM (3 mL) and shaken for 2 hours. 
Full cleavage of the Rink-amide peptides from resin along with removal of side chain 
protecting groups was achieved with a solution of 95% TFA, 2.5% TIPS and 2.5% water 
over 5 h. The cleaved peptides were precipitated in cold tert-butyl methyl ether (TBME) 
and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide dissolved 
in water, frozen at -78 °C, and lyophilized. The peptides were then purified by preparative 
reverse-phase HPLC-MS over gradients of acetonitrile (0.1% TFA) in water (0.1% TFA).  
The peptides were all isolated in >98% purity by analytical RP-HPLC. Peptides are a 
combination of the two inseparable regioisomers.  
4.1  
 
HRMS (ESI): m/z calculated for C64H84FN23O13 [M + H]
+: 1402.6681; found: 1402.6640 
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4.2 
 
HRMS (ESI): m/z calculated for C61H77FN16O11 [M + H]
+: 1229.6020; found:1229.5989  
4.3 
 
HRMS (ESI): m/z calculated for C55H66FN15O15 [M + H]
+: 1196.4925; found: 1196.4909  
4.4 
 
HRMS (ESI): m/z calculated for C63H85FN18O11 [M + H]
+: 1289.6708; found: 1289.665 
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4.5 
 
HRMS (ESI): m/z calculated for C59H86FN21O13 [M + H]
+: 1316.6776; found: 1316.6728  
4.6  
 
HRMS (ESI): m/z calculated for C60H77FN16O12 [M + H]
+: 1233.5983; found: 1233.5933  
4.7 
 
HRMS (ESI): m/z calculated for C53H70FN17O14 [M + H]
+: 1188.5350; found: 1188.5350 
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4.8 
 
HRMS (ESI): m/z calculated for C56H76FN17O10 [M + H]
+: 1166.6023; found: 1166.5992  
4.4.7 Radioligand Competitive Binding Assays 
In vitro CXCR4 affinity of hit peptides 4.1-4.8 were determined through competitive 
binding assays using U87.CD4.CXCR4 cells with [125I]-SDF-1α as the radioligand (Perkin 
Elmer). The compound of interest (30 µL, at concentrations ranging from 10−8 to 10−2 M) 
or buffer (30 µL as background control) and 20,000 cpm of [125I]-SDF-1α (20 pM) were 
mixed with the binding buffer (20 mM HEPES, 0.5% BSA in PBS, pH 7) in 1.5 mL 
Eppendorf Protein LoBind vials. A suspension of U87.CD4.CXCR4 cells (50,000 cells in 
50 µL) was added to each vial to give a final volume of 300 μL. The vials were shaken at 
550 rpm for 20 minutes at 37 °C. Immediately after the incubation, the vials were 
centrifuged at 13,000 rpm for 5 minutes and the supernatant removed. The cell pellet was 
washed with 500 μL of 50 mM Tris buffer (pH 7) and centrifuged again. The amount of 
[125I]-SDF-1α bound to the cells was measured using a gamma counter (PerkinElmer). 
Background uptake of the [125I]-SDF-1α onto vials was subtracted from all assay vials. IC50 
values were determined by non-linear regression analysis to fit a 4-parameter dose response 
curve using GraphPad Prism (Version 6.0c). All data points were obtained in triplicate. 
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Chapter 5  
5 Conclusions 
5.1 Summary and Outlook 
Molecular imaging is a rapidly expanding field due to the advent of new technologies that 
can be used for medical imaging. The ability to image cellular and metabolic targets as 
markers of disease with nuclear imaging techniques like PET and SPECT allows clinicians 
and scientists to learn more about these disease states, establish earlier diagnoses, and 
stratify patients based on biomarker presence, allowing for personalized medicine. The 
chemokine receptor CXCR4 is an interesting GPCR target that is present in over 23 types 
of cancers, while being absent in healthy tissue.1,2 Due to its involvement in chemotactic 
and angiogenic pathways, it is a potential marker for metastatic cancers. While some 
CXCR4 imaging agents have been developed, the only one to show clinical utility is 
[68Ga]Pentixafor, and no ideal fluorine-18 tracers have been yet established.3 This 
illustrates the need for the development of a toolbox of radiopharmaceutical imaging agents 
for CXCR4 and other markers that can be used to non-invasively determine patient-specific 
biomarkers. These new imaging agents can be developed based on a rational medicinal 
chemistry design from a known ligand-receptor interaction, which can be a lengthy 
process. When no such interaction is known, or the possible structures do not have an 
appropriate pharmacokinetic profile for imaging, new candidates must be discovered. This 
highlights a need for improved discovery methods with regards to receptor-targeted 
imaging agents.  
Unfortunately, the well-established high-throughput screening approaches that can be used 
to observe new drug-target interactions are not commonly translated into the discovery of 
new imaging agents. Ligands discovered from these screening campaigns still need 
modification into an imaging agent, which limits the utility of the approach. One-bead one-
compound (OBOC) libraries are a combinatorial method for synthesizing peptide 
libraries,4 and have the advantage of being able to synthetically incorporate non-amino acid 
structures. This approach serves as an ideal scaffold for the design of libraries of imaging 
agents.  
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In this research we explored the development of libraries of millions of imaging agents that 
included a fluorine atom as a surrogate for the placement of fluorine-18. This allows 
screening of the libraries to be performed on entire imaging agents, limiting the need for 
post-screening modifications. We developed the chemistry for two such libraries, and 
chose to employ strain-promoted alkyne-azide cycloaddition click (SPAAC) reactions5 to 
incorporate the fluorine in each. This reaction is particularly amenable to radiolabelling 
with fluorine-18 and the components can be introduced into peptides in a variety of ways.  
In Chapter 2, an OBOC library is described where the imaging moiety was placed on the 
N-terminus of the peptides. Since this placement of the imaging surrogate results in it 
projecting away from the bead, we proposed this would encourage discovery of imaging 
agents where the imaging entity was involved in receptor binding. We employed an 
existing SPAAC cyclooctyne as well as a reported azido fluorine PEG-based prosthetic 
group. Automated screening of this library against a CXCR4-expressing cell line resulted 
multiple hits, of which a hit with micromolar affinity to the receptor was discovered. 
Unfortunately, multiple obstacles were encountered during this process which limited the 
possibility of utilizing the library to its full ability for high-throughput imaging agent 
discovery. Firstly, multiple rounds of screening were necessary to establish high-affinity 
hits to the target, and screening was not inherently receptor-specific. Hit peptide sequences 
needed to be resynthesized to probe target specificity as well as affirm receptor affinity due 
to bead autofluorescence complicating automated screening. Secondly, de novo sequence 
deconvolution was hindered due to the high fragmentation percentage in the chosen 
cyclooctyne portion of the peptide, limiting observation of complete ion series in MS/MS. 
Isobaric amino acids included in the library also caused the need for synthesis of multiple 
possible iterations of hit sequences for in vitro affinity assays. We addressed these aspects 
in our second-generation imaging agent library described in Chapter 4.  
The purpose of the work described in Chapter 3 was to establish a novel fluorine-containing 
cyclooctyne that could be incorporated rapidly into azide-containing peptides by SPAAC 
for 18F-radiolabelling. Although other such cyclooctynes exist,6–9 we needed the 
cyclooctyne to be small enough to not impede receptor-peptide binding or have variable 
binding based on regioisomers, have minimal functionalities that would result in 
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fragmentation in MALDI MS/MS, and be synthetically accessible on a large scale for 
incorporation into our libraries. This resulted in the design and synthesis of our 
azadibenzocyclooctyne ADIBO-F.10 We were able to access this in eight steps, radiolabel 
it with fluorine-18 in good radiochemical yields, and showed its utility as a prosthetic group 
for radiolabelling biomolecules with fluorine-18 by subsequently clicking it into 
established cancer-targeting peptides. We demonstrated that its presence in relatively small 
peptides did not impede binding. This is a useful addition to the radiochemist’s toolbox of 
prosthetic groups for using mild conditions to afford 18F-labelled biomolecules and other 
targeting agents.  
Chapter 4 relays the design and synthesis of an OBOC library where the imaging moiety 
was able to be randomly dispersed within the peptide sequences. The cyclooctyne 
prosthetic group established in Chapter 3 allowed us this opportunity. We also approached 
the experimental design with obstacles from Chapter 2 in mind, and sought to overcome 
these challenges in this chapter. To this end, some sequencing complications were 
mitigated by completely removing isobaric amino acids from the library, and by employing 
a new cyclooctyne/azide pair with fewer possible MS/MS fragmentation locations. In 
addition, an on-bead two-colour screen11 was employed to search for hit peptide beads with 
both affinity and selectivity to the target in one step. This eliminated the need for multiple 
in-solution assays for hit confirmation.  
Aside from improving the library design, we were also able to demonstrate that multiple 
hits with micromolar affinity to the chosen receptor, CXCR4, could be discovered from 
this imaging agent library. The on-bead two-colour screening was simple and efficient, and 
has potential to be automated.12  
The libraries described herein serve as an excellent starting point for the development and 
expansion of libraries to find new imaging agents for any given target. Libraries of our 
design with other imaging components could be produced for any imaging entity of 
interest; this gives the potential to produce libraries of SPECT or PET tracers using other 
isotope mimics, MRI contrast agents using paramagnetic metal ions, or optical imaging 
agents using fluorescent moieties. Other fluorine-18 prosthetic groups could also be 
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explored that are smaller in size and have established radiolabelling methods. An imaging 
agent OBOC library with a 4-fluorobenzoyl-containing amino acid as the imaging 
surrogate was described recently.13 The fluorine-containing amino acid was fixed at the C-
terminus on the beads, and the remaining peptide sequences contained a known binding 
motif to the target of interest and was randomized at other locations. This library shows the 
promise in designing focused peptide-based imaging agent libraries as a method of lead 
optimization where peptide-target interactions have been previously explored. Pairing our 
newly designed imaging agent library approach with other classic OBOC approaches 
would improve upon any hits obtained from such libraries. For example, making OBOC 
libraries that incorporate non-canonical or D-amino acids into the synthesis could also 
result in peptide imaging agents that have better in vivo stability. Most research 
surrounding OBOC is currently focused on improving the automation of the screening and 
hit validation process to make the approach truly high-throughput. Therefore, combination 
of our application-based imaging agent OBOC approach with new bead-based screening 
technologies would only improve the throughput and efficacy of our discovery process. 
Importantly, OBOC technologies are being developed to establish more efficient screening 
steps,14,15 improve upon sequencing bottlenecks,16,17 and perform affinity assays from 
single bead quantities of peptide.18,19 Others have shown the utility of the OBOC approach 
in synthesizing libraries of various small molecules or peptoid structures, which would also 
be interesting scaffolds to incorporate an imaging component.20,21  
In summary, we have proved the usefulness of OBOC libraries in the discovery of new 
imaging agents for CXCR4. Hits with micromolar affinities to CXCR4 were discovered 
directly from library screens and are good candidates for lead optimization to improve upon 
affinity. New imaging agents for CXCR4 could be important in the early detection of 
metastatic cancers, and also in imaging of disease load for late-stage patients. With the 
advent of targeted radiotherapy, agents that are capable of imaging widespread metastatic 
cancers show potential for transformation into theranostic agents. Incorporating SPAAC 
into our library designs gives us the ability to immediately translate direct hits from the 
library into the radiolabelled counterparts. As part of this, we also developed a new 
synthetically accessible fluorine-18 prosthetic group for SPAAC radiolabelling, which can 
be useful for quick, clean 18F-labelling of any azide-modified structure.  
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Chapter 6  
6 Appendix – Additional Data for Chapter 4 
6.1 HPLC Traces for Hit Peptides 
Analytical UV chromatogram from RP-HPLC of purified 4.1 (15-85% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 9.21 min). 
 
  
Analytical UV chromatogram from RP-HPLC of purified 4.2 (25-85% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 7.83 min). 
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Analytical UV chromatogram from RP-HPLC of purified 4.3 (20-80% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.63 min). 
 
 
 
Analytical UV chromatogram from RP-HPLC of purified 4.4 (25-85% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.55 min). 
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Analytical UV chromatogram from RP-HPLC of purified 4.5 (20-80% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.74 min). 
 
 
 
Analytical UV chromatogram from RP-HPLC of purified 4.6 (25-85% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.98 min). 
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Analytical UV chromatogram from RP-HPLC of purified 4.7 (20-80% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.64 min).  
 
 
 
 
Analytical UV chromatogram from RP-HPLC of purified 4.8 (20-80% ACN/H2O, 0.1% 
TFA, 10 minutes, RT = 8.64 min) 
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6.2 IC50 Curves for Hit Peptides 
IC50 curve for 4.1 
 
IC50 curve for 4.2 
 
IC50 curve for 4.3 
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IC50 curve for 4.4 
 
IC50 curve for 4.5 
 
IC50 curve for 4.6 
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IC50 curve for 4.7 
 
IC50 curve for 4.8 
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6.3 MALDI MS/MS Deconvolution for Hit Peptides 
MALDI MS/MS of 4.1 
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MALDI MS/MS of 4.2 
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MALDI MS/MS of 4.4 
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MALDI MS/MS of 4.5 
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MALDI MS/MS of 4.6 
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MALDI MS/MS of 4.7 
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MALDI MS/MS of 4.8 
 
 
  
113 
 
Curriculum Vitae 
EDUCATION 
09/14-08/19 Doctor of Philosophy, Organic Chemistry and Molecular 
Imaging 
   University of Western Ontario, London, Ontario, Canada 
 
   Supervisor: Dr. Leonard G. Luyt 
Thesis: Incorporation of Fluorine into Peptides and Peptide 
OBOC Libraries through Copper-free Click Chemistry for the 
Development of Radiopharmaceuticals 
09/09-04/13  Honours Bachelor of Science, Chemistry 
    Certificate in Medicinal Chemistry 
   Dalhousie University, Halifax, Nova Scotia, Canada 
   Supervisor: Dr. D. Jean Burnell 
Thesis: Trapping of the Cationic Intermediate of the Nazarov 
Intermediate by Pyrrole and by Thiophenes 
 
HONOURS and AWARDS 
2019  J. Peter Guthrie Conference Travel Award  
2019  Society of Radiopharmaceutical Sciences ISRS 2019 Travel Bursary 
Award 
2019  Molecular Imaging Graduate Program Travel Bursary 
2018 Society of Radiopharmaceutical Sciences TERACHEM 2018 Travel 
Bursary Award (Education & Research Foundation for Nuclear Medicine 
and Molecular Imaging) 
2018 Molecular Imaging Graduate Program Travel Bursary 
2017  Society of Radiopharmaceutical Sciences ISRS 2017 Bursary Award  
2017  Molecular Imaging Graduate Program Travel Bursary 
2016  Oncology Research and Education Day Poster Award  
2013-2019 Western Graduate Research Scholarship 
 
 
PUBLICATIONS 
• Turnbull, W. L.; Yu, L.; Murrell, E.; Milne, M.; Charron, C. L.; Luyt, L. G. A 
dual modality 99mTc/Re(I)-labelled T140 analogue for imaging of CXCR4 
expression. Org. Biomol. Chem., 2019, 17, 598-608. 
• Murrell, E.; Kovacs, M. S.; and Luyt, L. G.  A Compact and Synthetically 
Accessible Fluorine-18 Labelled Cyclooctyne Prosthetic Group for Labelling of 
114 
 
Biomolecules by Copper-Free Click Chemistry. ChemMedChem. 2018, 13, 1625-
1628.  
• Simpson, E. J.; Gobbo, P.; Bononi, F. C.; Murrell, E.; Workentin, M. S.; and 
Luyt, L. G. Bombesin-functionalized water-soluble gold nanoparticles for 
targeting prostate cancer. Journal of Interdisciplinary Nanomedicine. 2017, 2, 
174–187. 
• Turnbull, W. L.; Murrell, E.; Bulcan-Gnirss, M.; Luyt, L. G. A Study of 
99mTc/Re-Tricarbonyl Complexes of 4-Amino-1,8-Naphthalimides. Dalton 
Transactions [Under Revision] 
 
PUBLISHED ABSTRACTS 
• Murrell, E.; Luyt, L. G.; A Combinatorial Library of Fluorine-Integrated 
Peptides for PET Imaging Agent Discovery. 23rd International Symposium on 
Radiopharmaceutical Sciences, 2019, J. Labelled Cpmds. Radiopharm. 62, S219.  
• Cho, C.-F.; Ghotmi, Y.; Fadzan, C.; Wolfe, J.; Bergmann, S.; Qu, Y.; Murrell, 
E.; Bononi, F.; Luyt, L.; Chiocca, E. A.; Viapiano, M.; Pentelute, B.; Lawler, S.; 
BTP-7, A novel peptide for therapeutic targeting of malignant brain tumors. 
Neuro-Oncology. 2018, 20 (suppl_6), vi74. 
• Murrell, E., Kovacs, M; Luyt, L. A novel fluorine-18 labelled 
azadibenzocyclooctyne prosthetic group for labelling of biomolecules by copper-
free click chemistry. 22nd International Symposium on Radiopharmaceutical 
Sciences, 2017, J. Labelled Cpmds. Radiopharm. 60, S590. 
• Cho, C.-F.; Ghotmi, Y.; Fazden, C.; Wolfe, J.; Bononi, F.; Murrell, E.; Luyt, L.; 
Viapiano, M.; Pentelute, B.; Chiocca, E. A.; Lawler, S. Novel peptide homing to 
glioma-specific isoform of brevican selectively targets malignant brain tumors. 
Neuro-Oncology. 2017, 19(suppl_6), vi62-vi63.  
 
OTHER CONFERENCE ABSTRACTS 
• Murrell, E.; Luyt, L. G.; Discovery of new CXCR4-Targeted PET Imaging 
Agents from a Combinatorial Library of Fluorine-Integrated Peptides. 16th 
Oncology Research and Education Day, June 14, 2019, London, ON, Canada 
• Murrell, E.; Luyt, L. G.; A Two-Pool Split-and-Mix Synthesis for Incorporating 
an Imaging Moiety into OBOC Libraries. 102nd Canadian Chemistry Conference, 
June 4 2019, Quebec City, Canada. [Oral Presentation] 
• Murrell, E.; Turnbull, W. L; Bulcan-Gnirss, M.; Luyt, L. G.; 99mTc/Re-
Tricarbonyl Naphthalimide Complexes for Dual Modal Fluorescence/SPECT 
Imaging Agents. 102nd Canadian Chemistry Conference, June 7, 2019, Quebec 
City, Canada. [Oral Presentation] 
• Murrell, E.; Turnbull, W. L; Bulcan-Gnirss, M.; Luyt, L. G.; Dual Modal 
Fluorescence/SPECT Imaging Probes: 4-Amino-1,8-naphthalimide 99mTc/Re-
Tricarbonyl Complexes. The Third International Symposium on Technetium and 
115 
 
Other Radiometals in Chemistry and Medicine, September 27, 2018, Bressanone, 
Italy. [Oral Presentation]  
• Murrell, E.; Luyt, L. G. Synthesis and Screening of a Combinatorial Library of 
Fluorine-Integrated Peptides for the Discovery of CXCR4-Targeting PET Agents. 
15th Oncology Research and Education Day, June 8, 2018, London, ON, Canada.  
• Murrell, E.; Luyt, L. G. Synthesis and Screening of a Combinatorial Library of 
Fluorine-Integrated Peptides for the Discovery of Cancer-Targeting PET Agents. 
Molecular and Cellular Imaging Symposium, May 1, 2018, London, ON, Canada. 
• Murrell, E.; Kovacs, M. S.; Luyt, L. G. A novel fluorine-18 labelled 
azadibenzocyclooctyne prosthetic group for click chemistry labelling of 
biomolecules to create cancer-targeted PET imaging agents. 14th Oncology 
Research and Education Day, June 16, 2017, London, ON, Canada. 
• Murrell, E.; Luyt, L. G. Incorporation of Fluorine into an OBOC Peptide Library 
by Copper-Free Click Chemistry for the Discovery of PET Imaging Probes. 100th 
Canadian Chemistry Conference, May 30, 2017, Toronto, ON, Canada. [Oral 
Presentation] 
• Murrell, E.; Luyt, L. G. A Fluorine-Containing OBOC Peptide Library for the 
Discovery of Cancer Imaging Probes. 15th Imaging Network Ontario Symposium. 
March 15, 2017, London, ON, Canada.  
• Murrell, E.; Luyt, L. G. A Fluorine-Containing OBOC Peptide Library for the 
Discovery of Cancer Imaging Probes. Imaging Applications in Prostate Cancer 
Workshop. November 25, 2016, London, ON, Canada.  
• Murrell, E.; Luyt, L. G. A Fluorine-Containing OBOC Peptide Library for the 
Discovery of Cancer Imaging Probes. 13th Oncology Research and Education 
Day. June 17, 2016, London, ON, Canada. 
 
TEACHING EXPERIENCE 
2018-2019 Mentor, Undergraduate Thesis Research (Marcus Tonogai),  
University of Western Ontario 
-Re/99mTc (I) Tricarbonyl Complexes of Cyclen and Cyclam Derivatives 
2017-2018 Mentor, Undergraduate Thesis Research (Mariel Bulcan-Gnirss),  
University of Western Ontario  
- A Study of the Fluorescent Properties of Rhenium Naphthalimide  
Complexes 
2014-2019 Marking & Laboratory Teaching Assistantships, University of Western  
Ontario                
     Medicinal Chemistry  
     Organic Chemistry I: Structure and Spectroscopy 
     Organic Chemistry of Biological Molecules 
     Organic Chemistry for Life Sciences     
     Organic and Biological Chemistry for Food Sciences 
     Chemistry: Everywhere and Everything 
     Western Integrated Science Program 
 
